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Abstract 
The mechanism by which remote ischaemic preconditioning (RIPC) exerts its cardio-
protective effects is not fully understood. Exosomes are lipid bound membranous 
vesicles that range from 30-100nm in size. With increasing interest in the scientific 
community about these vesicles as a mode of intercellular communication, in this 
project we explore the possible mechanistic role of human plasma exosomes in RIPC. 
We first developed a consistent and reliable model for the isolation of human plasma 
exosomes through a process of differential centrifugation and ultracentrifugation. 
Further scientific models for biomarker analysis and quantification of the isolated 
human plasma exosomes were developed and validated through western blotting and 
flow cytometry and nanosight analysis. In addition we successfully developed a 
protocol for the isolation of microRNA from our human plasma exosomes. Confident 
with our isolation and biomarker analysis models we investigated the content 
differences in human plasma exosomes isolated after a RIPC (3 cycles of fore arm cuff 
inflation and deflation) and compared those to control human plasma exosomes. Our 
results show that RIPC lead to a rise in plasma exosome concentration with a peak rise 
in exosome concentrations occurring only after the last 5 minutes of cuff deflation 
(reperfusion) in the 3 cycles of the RIPC protocol. We probed both RIPC and control 
human plasma exosomes for known pro-survival protein kinases of the RISK pathway 
(P13K, MEK 1/2, AKT, ERK1/2) though were not able to detect these in any sample. 
We then tested the hypothesis that the cardio-protection conferred through RIPC is 
mediated through circulating plasma exosomes. RIPC and control human plasma 
exosomes were added to an invitro model of ischaemia reperfusion using rat 
cardiomyocyte cells. Interestingly our results demonstrate that human plasma 
exosomes are cardio-protective against ischaemia reperfusion injury irrespective if they 
are control or RIPC plasma exosomes. The cardio-protection conferred by human 
plasma exosomes is comparable to Insulin, a known cardio-protective agent, used as 
our positive control. These results suggest that plasma exosomes in general are 
cardio-protective and may not have a mechanistic role in the cardio-protection 
conferred through RIPC.  Further experiments must be carried out to ascertain the 
exact mechanism through which human plasma exosomes confer cardio-protection.  
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CHAPTER 
 
Introduction 
Epidemiology and Burden of Cardiovascular Disease 
Cardiovascular disease (CVD), despite the advances of modern medicine and 
reduction in mortality rates, remains the number one cause of death globally. Figures 
from The World Health Organization show an estimated 17.1 million deaths from CVD 
in 2004 alone with a predicted rise to 23.6 million by 2030 1. This pattern is mirrored in 
UK mortality figures, with 180,000 deaths in England and Wales (2010) attributed to 
CVD 2. Around 46% of these deaths were due to coronary heart disease (CHD) and 
28% caused by a stroke 2. CHD is still the leading cause of death in the UK resulting in 
one in five male deaths and one in 6 female deaths. A study in 2002 estimated the total 
annual cost of all CHD related burdens as £7.06 billion, more than any other diseases 
for which comparable analyses have been done 3. The most recent figures published 
by the British Heart Foundation estimate the cost to the NHS of CVD related diseases 
to stand at around £8.6 billion in 2009 with an overall cost to the UK economy of £19 
billion a year taking into account productivity losses and cost of informal care 4. 
Coronary Heart Disease (CHD) 
CHD is the most common cause of heart disease worldwide. In the early 19th century, 
acute myocardial infarction (AMI) was generally regarded as a medical curiosity. In 
1880 it was Carl Weigert who first suggested the association between coronary 
occlusion and AMI. CHD arises from the accumulation of atherosclerotic plaque 
causing vascular dysfunction and resulting in compromised myocardial perfusion. CHD 
presents itself through a clinical spectrum of angina through to the acute occlusion of a 
myocardial infarction. The reduction in lumen size due to atheroma leads to a perfusion 
1 
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demand and supply mismatch that is exacerbated by exercise leading to angina. AMI 
occurs when there is an acute plaque rupture with subsequent thrombus formation 
resulting in total occlusion of the coronary artery. Up until 1950, the treatment for AMI 
was largely focused on palliation rather than curing the underlying process. In the 
1970’s Marako and colleagues first identified, in animal studies on dogs, that 
reperfusion of the occluded coronary artery would reduce the extent of myocardial 
damage5 6. In 1976, a Soviet team led by Chazov showed intra-coronary administration 
of streptokinase in patients with AMI within 4 hours of coronary occlusion, restored 
patency within approximately 50 min. This effect was not seen, however, when the 
duration of occlusion exceeded 10 h. This work has set the basis for all future 
developments of early myocardial reperfusion therapy for the treatment for AMI 7. 
Ischaemia Reperfusion Injury 
Primary percutaneous coronary intervention (PCI) and thrombolysis are currently the 
gold standard treatments for patients with an AMI. Paradoxically, however, the return of 
blood flow can also result in additional cardiac damage referred to as reperfusion injury 
(RI) and thus reducing the benefit of any reperfusion treatment undergone. Jennings 
and colleagues, first described RI, in 1960 through experiments with canine hearts 
which were subjected to coronary occlusion and reperfusion 8. They showed that 
reperfusion appeared to accelerate the development of necrosis. Reperfusion injury 
manifests clinically as four types of cardiac dysfunction; myocardial stunning, which 
refers to the reversible reduction in contractility of the heart following reperfusion that is 
not accounted for by tissue damage or reduced blood flow; reperfusion arrhythmias, 
which are common in patients who have had their coronaries re-opened either by 
thrombolytic therapy or primary percutaneous intervention (PCI) and is thought to be 
mediated by mitochondrial dysfunction 9; the no-reflow phenomenon, where despite 
opening of the previously occluded coronary artery blood fails to reperfuse the 
ischaemic area. This is thought to occur as a result of micro vascular damage 10. The 
last manifestation of ischaemia-reperfusion (IR) injury is termed lethal reperfusion 
injury. This is described as myocyte cell death due to reperfusion itself 11. 
Pathophysiology of ischaemia and reperfusion injury 
Despite reperfusion being necessary to salvage ischaemic myocardium, reperfusion 
initiates a cascade of events that lead to further death of previously viable cells. Initially 
ischaemia results in cessation of oxidative phosphorylation and inhibition of 
mitochondrial ATP synthesis. As a result the ischaemic cardiomyocyte must rely on 
12 
anaerobic glycolysis for its ATP supply. Anaerobic glycolysis leads to a buildup of 
lactate resulting in the acidification of the cytosol. The cell extrudes the H+ ions in 
exchange for Na+ via the sarcolemmal Na+/H+exchanger causing a rise in intracellular 
sodium. The high sodium concentrations cause the Na+-Ca2+ exchanger to work in 
reverse, which drives a slow increase in cytosolic and sarcoplasmic reticular Ca2+ 
concentrations. Reperfusion causes an acceleration of this process causing a further 
rise in sarcoplasmic Ca2+ which adds to the already Ca2+ overloaded cell. Ischaemia 
also causes a reduction in cytosolic pH that inhibits myofibrillar contraction, however 
reperfusion rapidly restores normal extracellular and intracellular pH and thus removing 
this acidic inhibition to contraction. The normalization of pH together with the rise in 
sarcoplasmic Ca2+ results in myocyte hypercontracture 12–15. 
Mitochondria play an integral role in the pathophysiology of ischaemia- reperfusion 
injury. The calcium overload from ischaemia and reperfusion causes the ordinarily 
impermeable mitochondrial membrane to allow the free movement of protons across 
the membrane 16. This change in permeability is largely thought to be mediated via a 
non-specific pore in the inner mitochondrial membrane called the mitochondrial 
permeability transition pore (MPTP)17. The opening of the MPTP results in 
mitochondrial swelling, outer membrane rupture and irreversible mitochondrial damage 
leading to necrosis 18. The production of detrimental reactive oxidative species (ROS) 
is a well-established consequence of IR which may be a consequence of mitochondrial 
damage 19,20.  Free radicals damage myocytes directly by altering membrane proteins 
and phospholipids. Additionally they trigger cellular injury through stimulating apoptosis 
and further stimulating opening of the MPTP, which then releases further free radicals 
in a catastrophic feedback 21,22. 
Other factors such as aggregation of leukocytes and inflammatory mediators, platelet 
and compliment activation are also thought to play a role in the pathophysiology of 
ischaemia - reperfusion injury, although this is more relevant at later stages after the 
initial injury 21,23. The release of leuckocytes into the extravascular space releases 
further elastases and proteases that destroy the cell membrane and cause cell death24. 
It is also thought that along with compliment activation neutrophil accumulation may 
contribute to the “no-reflow” phenomenon25,26. 
Damage to cardiomyocytes from IR injury is principally through necrosis, however 
apoptosis and the activation of pro-apoptotic signalling pathways are thought to 
contribute to reperfusion injury at later stages27. Studies carried out on rabbits have 
shown markers of apoptosis in reperfused tissue but not in either normal or ischaemic 
13 
tissue 27. Additionally further animal studies have shown that the addition of an 
apoptosis repressor reduces the extent of IR injury28. 
 
 
Figure 1  Mechanism of IR injury: IR leads to calcium influx and opening of the 
MPTP resulting in myocyte hypercontracture, opening of the MPTP and 
myocyte necrosis through the release of ROS and inflammatory 
mediators. 
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Ischaemic Preconditioning 
Ischaemic preconditioning is an intrinsic mechanism that protects a target organ from 
injury and cell death that would result from ischaemia and reperfusion. Murry et al first 
described this process in their seminal paper in 1986 29. The study involved 
anaesthetised dogs subjected to four 5-minute periods of coronary artery occlusion 
followed by reperfusion. The dogs were then subjected to a more sustained 40-minute 
period of coronary artery occlusion. When compared to controls i.e. dogs that did not 
receive the preconditioning stimulus, the preconditioned dogs had significantly reduced 
infarct sizes. Prolonged ischaemia leads to depletion of ATP and myocyte necrosis. 
Murry et al showed that ATP levels fell only during the first cycle of IR and during 
subsequent ischaemic episodes ATP levels were preserved 29. Since the publication of 
this paper ischaemic preconditioning has been shown to be effective in reducing infarct 
size across a multitude of animal species. These species now include dogs 29, pigs 30, 
sheep 31, rabbits 32, rats 33, marmots 34 and ferrets 35. 
Mechanisms of Ischaemic Preconditioning 
Ischaemic preconditioning can be sub divided into two phases early and late. Early or 
Classical preconditioning occurs immediately after the preconditioning stimulus and its 
protective effects last for 1-2hrs 36. Late or delayed preconditioning refers to a “second 
window” of protection (SWOP), where the cardio-protective effects of preconditioning 
disappear after 2 hours yet reappear 24 hours later 37,38. It was Downey and colleagues 
who first described in rabbit hearts the triggering of protective mechanisms of 
ischaemic preconditioning via the adenosine A1 receptor 39. Since then it is accepted 
that protection is a receptor-mediated process. In the early phase of ischaemic 
preconditioning adenosine, bradykinin and opioids are released 40. These substrates 
bind to their G-protein receptors on the myocyte sarcolemmal membrane. The 
occupation of these receptors leads to activation of pro-survival kinases that confer 
cardio-protection. These pro-survival kinases, phosphatidylinositol-3-OH kinase (PI3K)-
Akt and the p42/p44 extracellular signal-regulated kinases (Erk1/2) have been termed 
the reperfusion injury salvage kinase (RISK) pathway and play an important target for 
cardio-protection 41. The RISK pathways result in the opening of the ATP-dependent 
mitochondrial potassium channel and conversely prevent opening of the mitochondrial 
transition pore and thus convey cardio-protection 42. The mechanism of cardio-
protection through classical preconditioning is complex. In addition to the RISK 
pathway additional pathways have also been suggested to play a mechanistic role in 
cardio-protection such as the GPCR/NPR-AKT-eNOS-PKG pathway 43 and the gp130-
15 
JAK-STAT pathway 44. The mechanism of delayed preconditioning shares many 
similarities with classical preconditioning. However delayed preconditioning appears to 
be dependent on the triggering of ROS 45 and nitric oxide which go on to facilitate de 
novo protein synthesis of distal mediators such as iNOS and COX-2. These mediators 
are thought to mediate the cardio-protection seen 24 hours after the initial 
preconditioning stimulus. Heat shock proteins such as HSP27 46, HSP70, the 
transcription of eNOS have been shown to play a cardio-protective role in delayed 
preconditioning 47. Work done by the Yellon’s group has shown the activation of the 
RISK pathway at the time of reperfusion protects the heart from IR injury 48. This 
presents an opportunity for clinical translation of cardio-protection. Work done by Zhi-
Qing Ahao et al, using anaesthetized dogs which had their LAD ligated and reperfused, 
showed that dogs that had intermittent cycles of reperfusion and occlusion prior to full 
reperfusion (Post-conditioning) were similarly cardio-protected when compared to dogs 
that had the classical preconditioning stimulus prior to infarction 49. Ischaemic post 
conditioning has shown to share common signalling pathways as ischaemic 
preconditioning. The finding of cardio-protection from ischaemic post-conditioning 
therefore suggests there still a window of protection that can be utilized even once 
infarction has taken place.  
16 
 
Figure 2 Diagram of RISK pathway and its effect on the mitochondrial permeability 
transition (MPT) pore. Conditioning stimulus exerts a cardio-protective 
effect through the activation of G protein-coupled receptors. This leads to 
activation of PI3K-Akt) and MEK1/2. Further downstream these further 
activate ERK ½, AKT, ENOS P70S6, and GSKβ. This cascade of pro-
survival kinases leads to the inhibition of MPTP conferring cardio-
protection. 
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Remote Ischaemic Preconditioning 
A group led by Przyklenk examined the hypothesis that brief episodes of ischemia 
applied in one coronary vascular bed would confer cardio-protection from infarction in 
another coronary territory. In anaesthetized dogs, the group were able to show that 
brief episode of ischaemia and reperfusion in the LAD territory would reduce the infarct 
size from a subsequent circumflex coronary artery infarction 50. This for the first time 
opened up the possibility of protecting the heart through conditioning another distant 
organ or non-cardiac tissue. Subsequent studies have shown the ability to protect the 
heart from IR injury by applying the preconditioning stimulus to other organs such as 
the kidney or small intestine. This phenomenon is now termed ‘remote ischaemic 
preconditioning’ (RIPC) 51 52. While these findings of are extremely exciting their clinical 
translation has been limited by the invasiveness of intervention needed. The critical 
break through resulted from the discovery that brief periods of transient limb ischaemia 
could also exert similar cardio-protective effects of RIPC. The first discovery was made 
by Birnbaum and colleagues, where they showed that restriction of blood flow to lower 
limb skeletal muscle and pacing of the gastrocnemius muscle prior to myocardial 
infarction in rabbits reduced infarct size 65% 53. Oxman and colleagues further 
developed this concept and went on to show that by simply applying a tourniquet to the 
hind limb, inducing 10 min of limb ischaemia in an IR model, significantly reduced 
reperfusion arrhythmias in rat hearts 54. However the discovery that limb ischaemia 
delivered easily and non-invasively by means of inflation of a blood pressure cuff 
exerting similar cardio-protective effects of RIPC has paved the way for its translation 
into clinical practise. MacAllister and colleagues undertaking experiments on human 
volunteers pioneered this area of research. In their studies volunteers were subjected 
to brief limb ischaemia, achieved through the inflation of a blood pressure cuff to 
200mmHg. Volunteers were given 3 cycles of 5 minutes of limb ischaemia (cuff 
inflation) followed by 5 minutes of reperfusion (cuff deflation) 55. The contralateral arm 
was then subjected to a 20-minute ischaemic period through blood pressure cuff 
inflation and the subsequent endothelial dysfunction analysed. Their results showed a 
reduction in endothelial dysfunction in those who had undergone a RIPC stimulus on 
the other arm 55 . Similarly with classical preconditioning, RIPC in its clinical translation 
is restricted to elective cardiac surgery where the index ischaemia can be predicted. 
Like ischaemic post conditioning, RpostC, where transient distal ischaemia is applied 
after infarction but prior to reperfusion, also offers the possibility of applying this cardio-
protective strategy to patients presenting with an AMI. Encouragingly using the same 
model MacAllister and colleagues were also able to show similar results with RPostC 
as well as a second window of protection 24-48hrs later similar to preconditioning 
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ref.  Andreka and colleagues explored the use of RPostC in pig hearts further. RPostC 
was induced in pigs by four 5 minute cycles of blood pressure cuff inflation applied to 
the lower limb immediately after inducing a left anterior descending artery MI. Results 
showed a 26% reduction in infarct size when compared to their control group 56.  
Myocardial mechanism of RIPC 
The mechanism by which RIPC exerts its cardio-protective effects is not fully 
understood.  Many of the signaling pathways implicated in pre and post conditioning 
have also been suggested to play a role in RIPC 57 58. However it is still uncertain 
whether RIPC results in activation of pro-survival kinases of the (RISK) pathway and 
the subsequent inhibition of the mitochondrial permeability transition pore (mPTP), as 
in IPC and IPOST 59.  Heidbreder and colleagues tested the hypothesis that mitogen-
activated protein kinases (MAPKs) JNK, p38 and Erk1/2 play a mechanistic role behind 
the cardio-protection offered from limb-mediated RIPC in rats. Their results 
demonstrated a loss of cardio-protection in RIPC treated rats after the addition of 
MAPK inhibitors SB203580, PD98059, and SP600125. Additionally RIPC resulted in a 
considerable increase in phosphorylation of ERK1/2 and JNK1/2 proteins in the small 
intestine whereas it did not alter the MAPK phosphorylation state in the myocardium 60. 
RIPC stimulus of a distal organ is thought to result in a release of humoral factors that 
are transported to the heart which in turn result in the activation of transduction 
mechanisms within the cardiomyocyte. These humoral factors bind to plasma G-protein 
coupled receptors, which activate intracellular kinases such as ERK1/2, PI3K/Akt, 
PKC-ε, etc. In particular studies have shown myocardial PKC-ε activation in response 
to binding of the bradykinin B2 receptor and in response to the mediator CGRP 61 62. 
Wolfrum and colleagues investigated the mechanism further and were able to 
demonstrate the loss of cardio-protection from RIPC by the non-specific PKC blocker, 
chelerythrine 63 64 65. Humoral factor binding to G-protein coupled receptors also leads 
to activation of other signaling components such as nitric oxide (NO) and the 
mitochondrial KATP channel, although it must be recognized that the very existence of 
this channel remains controversial 66 65 67 68. There have been several studies that have 
linked the opening of these channels to RIPC using pharmacological antagonists of the 
KATP channels such as glibenclamide and 5-hydroxydecanoate 65 67 69. In addition 
Weinbrenner et al showed that a free radical scavenger was able to abolish the 
protection elicited by RIPC, thus suggesting a role for reactive oxygen species (ROS) 
in the mechanistic pathway in RIPC 70.  
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From Distant Organ to the Heart 
The mechanistic pathway from distant organ to the heart remains unclear. Current 
thoughts are that there are three main mechanisms: humoral, neural, and systemic, 
which interact with each other, conferring protection upon the target organ from a 
distant site. 
• Humoral 
Numerous studies have shown that a humoral factor appears to play a role in the 
mechanism of cardio-protection offered through RIPC. Dickson and colleagues 
hypothesized that if the trigger signal responsible for RIPC is humoral in nature 
then it should be transferable from one animal to another of similar species. Using 
paired, blood cross-matched rabbits, the group were able to show that the remote 
preconditioning effect could be transferred from one preconditioned rabbit to a non-
preconditioned rabbit heart via whole blood transfusion 71 72. Further evidence that 
RIPC involves a humoral mediator comes from work done by Konstantinov et al. 
Their results showed limb RIPC of pigs that had received a transplanted hearts was 
able to reduce myocardial infarct size in the donor heart 67. Identification of the 
humoral factor or factors that conveys protection from RIPC is proving a challenge, 
particularly because they may be active at very low concentrations amongst the 
huge protein content of the blood. Shimizu and colleagues showed, in a 
Langendorff isolated rat heart model, that prior -perfusion with either the plasma 
from donor rabbits subjected to RIPC similarly protected against infarction. The 
effectiveness of the RIPC plasma was lost after passage through a hydrophobic 
column, but eluate from this column provided the same level of protection, 
suggesting the factor is hydrophobic. The plasma was dialysed to remove low 
molecular weight components, and protection was lost, suggesting that the 
protective factor is of a low molecular mass (<15kda).  The group additionally 
showed similar results using dialysate of RIPC plasma from humans, in an in vitro 
cardiomyocyte model of IR, showing increased protection when compared to 
control. Similar studies have narrowed down the protective factor to a range of 3.5 
kDa to 15 kDa 73,74 but proteomics has yet to reveal the identity of the peptide. 
Humoral factors such as bradykinin, opioids, adenosine and endocannabinoids 
have all been investigated since many are involved in direct IPC and are therefore 
obvious potential candidates for RIPC. There is increasing evidence for opioid 
receptor involvement in the cardio-protective mechanism of RIPC 75–77.  It is 
hypothesized that endogenous opioids are generated by the RIPC stimulus in the 
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remote donor organ, which then enter the blood stream and then act directly on the 
myocardium to confer cardio-protection. Patel and colleagues first demonstrated 
that naloxone, a non-specific opioid receptor blocker, was capable of abolishing the 
protection conferred by mesenteric RIPC in rats. Shimizu and colleagues explored 
this further using RIPC dialysate, with which they discovered cardio-protection was 
also lost after the addition of naloxone 78. Both the δ1-opioid receptor and the κ-
opioid receptor have been implicated in RIPC cardio-protection 79 70 80. However the 
relative contributions to cardio-protection from these different opioid receptor 
subtypes remain unclear. 
Bradykinin has been found to be a key mediator in ischaemic preconditioning. Work 
carried out by Schoemaker and colleagues also suggest its involvement in RIPC. 
Their results showed the protective effects of RIPC through brief mesenteric artery 
occlusion was lost through the administration of a HOE-140, a bradykinin B2 
receptor antagonist 81. However more recently a study in human volunteers 
investigated further the role of bradykinin in RIPC in human volunteers. 
Endothelium-dependent vasomotor function as investigated in human volunteers 
who were given a RIPC protocol with and without the bradykinin B2 receptor 
antagonist (HOE-140). Their results showed no difference in the impairment of 
endothelium-dependent vasomotor function in volunteers who had been given 
RIPC and a bradykinin B2 receptor antagonist compared to volunteers who had 
been treated with RIPC alone. Both showed significant reduction in the impairment 
of endothelium-dependent vasomotor function when compared to the non-RIPC 
treated control volunteers 82. Yellon’s group first described the mechanistic role of 
adenosine in RIPC. The reduction in myocardial infarct size achieved through renal 
artery RIPC was found to be lost after administration of the non-specific adenosine 
receptor antagonist 8-sulphophenyltheophylline (8-SPT) 65. While this data 
suggests adenosine receptor binding is involved during RIPC, Takaoka and 
colleagues demonstrated that adenosine receptor binding is also required for 
cardio-protection, in experiments in which 8-SPT was administered after the RIPC 
protocol but prior to the extended ischaemia83.  Increased plasma levels of 
adenosine has also been found in blood taken from the carotid artery of rabbits 
subjected to RIPC when compared to rabbits treated with IPC alone 84. Most 
recently other humoral factors such as interleukin 10 and SDF-1α have, in addition, 
been implicated in playing a mechanistic role in RIPC 85,86. It is highly plausible that 
multiple humoral factors are involved in the mechanism of protection behind RIPC. 
These factors are not mutually exclusive and may operate in parallel or in series. 
However how they get from the distant organ to the heart is yet not known. Transfer 
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may well be via the blood stream however many humoral proteins such as SDF1α 
are highly labile or subject to proteinase degradation. There may be protective 
mechanisms that prevent this degradation that allow safe transfer and further 
investigation is needed. 
• Neural Pathway 
Some have hypothesized that neural pathways may play an important role in the 
protective mechanisms that underpin RIPC. Evidence shows that these neural 
pathways work in conjunction with the humoral factors mentioned previously. 
Having demonstrated the involvement of bradykinin as cited above, Gho and 
colleagues went on to demonstrate that the protection conferred through intra 
mesenteric administration of bradykinin was sensitive to ganglion blockade by 
hexamethonium 51. They hypothesised that bradykinin stimulated by RIPC may 
then go on to stimulate mesenteric afferent sensory nerves which then go on to 
mediate the cardio-protective effects of RIPC. Thus both pathways may be involved 
serially. Further evidence of a neural pathway came from work done by Ding et al. 
The group showed that cardio-protection from renal artery-RIPC was lost after renal 
nerve section. They also demonstrated increased renal nerve discharge during a 
renal preconditioning stimulus. Interestingly they additionally showed that this 
increase in renal nerve discharge was also blocked by administration of 8-PT. Thus 
like bradykinin it seems, adenosine may exert it effects via neural pathways 87. 
Liem and colleagues further investigated this hypothesis. They were able to confer 
cardio-protection via administration of adenosine into the mesenteric vascular bed 
and as per Schoemakers’ work with bradykinin, cardio-protection was lost after 
ganglion blockade with hexamethonium 88. These findings suggest similarly to 
bradykinin that the renal artery RIPC stimulus leads to increased adenosine 
concentration, which activates mesenteric afferent nerves, which in turn mediate 
cardio-protection. Work carried out by Dong and colleagues shows evidence for a 
neural pathway extending beyond renal RIPC stimulus. In their experiments, they 
demonstrate the cardio-protective effect of remote hind limb preconditioning was 
obliterated by femoral nerve dissection, suggesting the need for an intact neural 
pathway for cardio-protection via RIPC. They were also able to demonstrate the 
role of adenosine in reduction in myocardial infarct size through direct intra-femoral 
artery administration of adenosine. 89 Tang et al have additionally suggested the 
neurotransmitter, calcitonin gene-related peptide (CGRP) as a potential mediator in 
RIPC. Through their experiments they conclude that RIPC stimulates capsaicin-
sensitive sensory nerves which release CGRP, which is carried to the heart in the 
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blood stream where it exerts a cardio-protective 90. It is therefore clear that neural 
pathways play a key mechanistic role in cardio-protection conferred through RIPC. 
Endogenous humoral substances such as adenosine and bradykinin released by 
the remote preconditioned organ go on to stimulate afferent nerve fibres, which 
then relay to efferent nerve fibres terminating on the myocardium to confer cardio-
protection.  
• Systemic Inflammatory response 
There have been several studies that have shown a systemic inflammatory 
response to RIPC. Work carried out on humans and rats by Konstantinov IE and 
colleagues showed suppression of genes encoding proteins involved in cytokine 
synthesis, leukocyte chemotaxis, adhesion and migration, exocytosis, innate 
immunity signaling pathways, and apoptosis. Interestingly suppression of these 
genes took place within 15 min of the RIPC protocol and even more so after 24 h 
67. This suggests RIPC induces global myocardial genomic responses that lead to 
increased resistance to ischaemic and oxidative stress both early and late after the 
stimulus. Furthermore, the rapidity of the response suggests the possibility of active 
mechanisms at mRNA suppression such as miRNA. Indeed the few clinical trials 
looking at the inflammatory response to RIPC have shown increases in 
inflammatory markers such as C-reactive protein and Interleukin-691,92.  
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Figure 3 Diagram representing the mechanism of RIPC. It is hypothesised that 
the RIPC stimulus of a distant organ such as kidney, forearm, leg or 
small intestine leads to stimulation of neuronal and humoral pathways 
as well as activation of a systemic inflammatory response. This then 
activates the sarcolemal GPCR and exerts cardio-protective effects via 
the traditional RISK pathway. 
 
Preconditioning in the Clinical Setting 
Human Atrial Trabaculae 
The majority of evidence for preconditioning the myocardium comes from animal 
studies with the effects being extrapolated to humans. This therefore potentially 
introduces errors due to species differences. Preconditioning as a cardio-protective 
strategy in humans has not been easily translated into routine clinical use as clinical 
trials assessing the use of preconditioning in humans have been challenging. This is 
largely due to ethical constraints of investigating with human participants together with 
the inability to reliably predict an onset of myocardial infarction. The human atrial 
trabaculae model of IR provides one solution to the above problems. This experimental 
model was first established in by Yellon’s laboratory and is both a robust and 
reproducible technique for assessing cardio-protective treatment strategies using 
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human atrial trabeculae subjected to simulated IR injury. Work from within our group 
was the first to show that preconditioning the human atrial tissue by brief periods of 
simulated ischaemia and reperfusion improved percentage recovery of tension after a 
sustained period of simulated ischaemia, when compared to control. 93 Importantly this 
model has also allowed for the allowed for assessment of the cardio protective 
signalling pathways seen in animal studies to be confirmed in human muscle93,94. 
Pre-Infarction Angina 
It is hypothesized that pre-infarction angina may represent a form of “natural” 
preconditioning caused by antecedent episodes of transient ischaemia and 
reperfusion. There have therefore been a number of studies that have looked at 
outcomes of those patients presenting with AMI with and without pre-infarction the 
results of which provide an indication that the human myocardium may be amenable to 
preconditioning. Studies have shown that patients with a history of pre-infarction 
angina have a more favourable outcome than those without prior angina. Interestingly, 
this benefit was not seen in diabetics and the elderly, groups that are also difficult to 
precondition in animal studies, although in this setting preconditioning is possible but it 
appears that the threshold for protection is raised in diabetes and age 95. Patients 
presenting with myocardial infarction who have had pre-infarction angina have been 
found to have less release of cardiac enzymes 96–98. Patients with pre-infarction angina 
have been shown to have a greater degree of myocardial viability in the infarcted area 
99; Improved left ventricular function and reduced frequency of severe congestive heart 
failure when compared to those that have not 97,98,100–102. Pre-infarction angina is also 
associated with a reduction in life threatening ventricular arrhythmias and reduced in 
hospital and one year mortality 97,98. These effects of pre-infarction angina were 
independent of cardiac risk factors, medical therapy and coronary collateral score 98,99. 
In another parallel to animal study models, and with similarities to the time course of 
protection seen in the “second window” of protection, pre-infarction angina appears 
only protective if it occurs within 24 to 48 hours of myocardial infarction.  
Warm up angina 
 “Warm up “ angina refers to the observation that exercise-induced ischaemia on 
second effort is significantly attenuated or even abolished if separated from first effort 
by a brief rest period 103. If we hypothesis that the initial exercise induced ischaemia is 
acting as a preconditioning stimulus therefore the phenomenon of “warm up” angina 
provides us with anecdotal evidence that the human heart may be amenable to 
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preconditioning. Though the mechanism behind the phenomenon of warm up angina is 
yet to be fully understood, the findings thus far indicate a process of prompt metabolic 
adaptation of the myocardium, which induces tolerance to subsequent ischemia, a 
process similar to classical preconditioning. 
Coronary artery bypass grafting (CABG)  
Patients who undergo CABG provide suitable candidates or the investigation of 
preconditioning in humans. Though it can be argued that the ischaemia associated with 
CABG surgery is different from that experienced from an AMI, in which CABG patients 
often experience a global ischaemia as compared to the regional ischaemia 
experienced from an AMI. These patients are undergoing a planned procedure, which 
inevitably causes a degree of myocardial ischaemia and reperfusion injury that can 
potentially be targeted by a preconditioning stimulus.  Yellon’s group first studied this in 
1993 in 14 patients undergoing CABG randomized into two groups. The 
preconditioning stimulus involved intermittent application of an aortic cross clamp to 
deliver repeated episodes of global ischaemia. Measurements of ATP levels in 
myocardial biopsies of the patients were used as the endpoints. Results showed those 
patients subjected to the preconditioning stimulus had better preservation of ATP levels 
in their myocardial biopsies104,105. These metabolic changes show stark similarities to 
those seen in a dog model of ischaemic preconditioning 105. Using the same protocol a 
further study by Yellon’s group measured the degree of serum troponin leak as a 
marker of myocardial necrosis. Results showed the preconditioned patients at 72 hours 
post surgery had significantly lower serum troponin T concentrations than those who 
were not preconditioned 106. Though these studies have shown some encouraging 
results, the application of direct preconditioning in cardiac surgery has been met with 
resistance because intermittent cross-clamping can prolong surgery by up to 30 
minutes which in turn increases the risk of other procedure-related complications such 
as the risk of embolism etc. Noticeably the addition of preconditioning to other cardio-
protective strategies such as hypothermia or cardioplegia, has not delivered any 
additional benefit 107,108. 
Percutaneous coronary intervention  
Percutaneous coronary intervention remains the gold-standard treatment for an AMI, 
thus the ability to precondition the human myocardium in this setting would provide an 
invaluable tool in the treatment of this disease process and reduce the degree of 
myocardial injury caused by the intervention itself. The procedure usually involves 
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repeated intracoronary balloon inflations with intervening periods of perfusion. Studies 
have examined the hypothesis that the first period of ischaemia may enhance the 
myocardial tolerance to subsequent balloon inflations via classic ischemic 
preconditioning. Studies have consistently shown that first balloon inflation longer than 
60-90 seconds significantly attenuate a number of markers of myocardial injury during 
subsequent balloon inflations. These markers include lactate production, release of 
myocardial enzymes, angina severity, left ventricular regional wall motion 
abnormalities, ST-segment elevation, QT dispersion and ventricular ectopic activity 109–
115. KATP channels, adenosine and bradykinin appear to play a mechanistic role in the 
increased tolerance to successive balloon inflations during PCI 116. Studies in human 
volunteers where patients were administered IV adenosine and bradykinin separately 
showed that both mirrored the protective effects of the first balloon inflation 117,118. As in 
animal experiments, opioid receptors too have been implicated. In a study of 20 
patients, administration of naloxone was able to abolished the protective adaptation to 
ischemia observed from the first prolonged balloon inflation 119. 
Clinical application of remote ischaemic preconditioning (RIPC) 
The advantages of RIPC when compared to local ischaemic preconditioning lie with its 
non-invasive nature and ease of application. Additionally local ischaemic 
preconditioning runs the risk of further myocardial dysfunction, low cardiac output, risk 
of arrhythmia, or secondary organ injury, this in comparison to the largely benign 
effects of transient skeletal muscle ischaemia. There is great interest in the clinical 
translation of RIPC as a cardio-protective strategy. RIPC in the setting of 
cardiovascular disease has been largely evaluated in three clinical settings; prior to 
cardiac surgery; prior to percutaneous coronary intervention and lastly in patients 
presenting with ST elevation myocardial infarction. 
Cardiac Surgery 
Günaydin and colleagues were one of the first to study the effects of remote ischemic 
preconditioning in 8 patients who were undergoing coronary artery bypass grafting 
(CABG). Participants were randomised to receive either RIPC (forearm cuff inflated to 
300 mmHg for 2 cycles of 3 minutes) or control. Blood samples were collected 
immediately before cardiopulmonary bypass, prior to de-clamping aorta and 5 min after 
de-clamping the aorta, to determine creatinine phosphokinase (CPK), CPK-MB and 
lactate dehydrogenase (LDH) levels. The study demonstrated an increase in lactate 
dehydrogenase (LDH) in the preconditioned group. According to previous reports, 
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preconditioning of the myocardium results in a beneficial decrease in anaerobic 
glycolysis resulting in less acidosis and accumulation of lactate 120. Though the results 
of this study show an increase in lactate dehydrogenase in the preconditioned group. 
Günaydin and colleagues hypothesized that preconditioning appeared to protect 
myocardium by enhancing anaerobic glycolysis. It is not clear how one can draw this 
conclusion from this study. The study is grossly underpowered with only 8 patients and 
shows contradictory results to what one would expect.  As previously described with an 
increase in glycolysis one would expect a corresponding decrease in LDH in the 
preconditioned group. 121 In this study we see the opposite. In fact is the increase in 
LDH seen in the preconditioned group as a result of increased cell death? In 2006 
Cheung and colleagues carried out a randomised controlled trial investigating RIPC in 
37 patients undergoing paediatric surgery for congenital cardiac defects. The results 
showed that the RIPC protocol of 4 cycles of 5 minute lower limb ischemia via cuff 
inflation prior to surgery was effective in reducing troponin levels, postoperative 
inotropic requirements, and airways resistance at 6 hours 122. An interesting study by 
Zhou W et al attempted to look at utilizing the protective effects of both classical RIPC 
and the “second window” of protection of RIPC. Patients undergoing ventricular septal 
defect repairs were randomised to a preconditioning group receiving three 5-min cycles 
of blood pressure cuff induced, limb ischaemia 24 hours before, and then again 1 hour 
before surgery. Results showed a reduction in cardiac enzyme release (LDH, CK and 
troponin I) post surgery in the preconditioned group. Additionally the preconditioned 
group also demonstrated reduction in inflammatory cytokine markers (IL-6, IL-8, IL-10 
and TNF-α) and improvement in lung compliance 123. In 2007, Yellon’s group 
investigated the role of RIPC in the context of 57 patients undergoing CABG. A 
reduction in troponin T levels was observed in those patients randomized to receiving a 
RIPC protocol of 3 cycles of 5-minute forearm cuff inflation to 200 mmHg after 
induction of anaesthesia and prior to surgery 124. In 2009 they went on to demonstrate 
a similar reduction in post-operative troponin I by administration of the same RIPC 
protocol in patients undergoing cold blood cardioplegia 125. Disappointingly, in 2010 a 
larger, single-centre study of 162 patients undergoing CABG who were randomised to 
receive either three, 5-minute cycles of upper limb cuff inflation to 200 mmHg and 
deflation or placebo demonstrated that RIPC did not attenuate troponin release, 
improve hemodynamics, or enhance renal or lung protection 126. The reasons for these 
divergent findings are not clear. An inadequately powered study is the most likely 
cause for a false negative in this study, if indeed it truly is a false negative. Interestingly 
in all the positive studies of RIPC in the context of CABG surgery, the RIPC stimulus is 
administered prior to cardiac surgery however in this one negative study the RIPC 
stimulus is administered after surgical incision.  
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A further 3 studies in 2010 were carried out investigating RIPC as a cardio-protective 
strategy in the context of CABG surgery.   The first a study by Thielmann and 
colleagues demonstrates a 44.5% reduction of area under the curve for Troponin I 
levels at 72 h for patients given a RIPC protocol who had undergone elective CABG 
surgery with crystalloid (Bretschneider) cardioplegic arrest127. Following this a study by 
Wagner and colleagues investigated whether one could confer similar protection 
through RIPC via the “second window” of protection in patients undergoing CABG with 
cold-crystalloid cardioplegia 127. An RIPC protocol of three five-minute cycles of upper 
limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 
40 mmHg more than the patient’s actual blood pressure was given to patients 18 hours 
before the procedure which resulted in a significant reduction in post operative troponin 
levels when compared to control 128. Hong and colleagues studied the effect of RIPC 
on 130 patients undergoing off-pump coronary artery bypass graft surgery (OPCABG). 
An RIPC stimulus four cycles of five-minute ischaemia and reperfusion on the upper 
limb using a pneumatic cuff resulted in a 26% reduction in area under the curve for 
postoperative Troponin I levels when compared to control, though this did not reach 
statistical significance 129. Hong and colleagues revisited this hypothesis in 2012 in 35 
patients scheduled for OPCABG to receive an RIPC and a remote post conditioning 
(RIPostC) protective strategy compared to a control group. In the RIPC+RIPostC 
group, 4 cycles of 5-min ischemia and 5-min reperfusion were done on a lower limb 
before anastomoses (RIPC) and after anastomoses (RIPostC). Results this time 
showed those patients who had RIPC+RIPostC strategy had significantly reduced 
postoperative serum troponin I levels with the area under the curve for postoperative 
troponin 48.7% lower in the RIPC+RIPostC group when compared to controls 130. 
Interestingly a study by Karuppasamy and colleagues in 2011 in 54 patients referred 
for elective CABG surgery who were randomized to receive the standard RIPC protocol 
of three 5 minute cycles of left arm cuff inflation and deflation or control, showed no 
difference in post operative troponin levels between the two groups. In this study 
patients were given an anaesthetic regimen of both isoflurane and propofol 131.  
Kottenberg and colleagues hypothesized RIPC had differential effects depending on 
background anaesthesia given. In there study of 72 patients undergoing CABG 
surgery, serum troponin I concentration at various time points were measured during 
isoflurane/sufentanil or propofol/sufentanil anaesthesia with or without RIPC. 
Interestingly their results demonstrates RIPC during isoflurane but not during propofol 
anaesthesia was able to attenuate myocardial damage 132.  In 2012 D’Ascenco and 
colleagues carried out a meta-analysis of the nine studies mentioned above with 704 
patients included. Standardised mean difference of troponin I and T release showed a 
significant decrease in the groups treated with an RIPC protocol (-0.36 (95% CI -0.62 
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to -0.09)) 133. More recently Yang et al carried out a larger meta-analysis of nineteen 
randomized trials involving 1,235 patients. The cTnI concentrations at 6 (or 4-8) hours 
postoperatively and the total cTnI released after surgery showed a statistically 
significant reduction in the RIPC group compared with a control group. In addition the 
group found no differences in mortality, morbidity, and resource utilization between 
groups134. Heusch and colleagues attempted to look at the effect of RIPC on mortality 
in patients undergoing elective CABG. They enrolled 329 patients scheduled to 
undergo elective, isolated first-time CABG under cold crystalloid cardioplegia and 
cardiopulmonary bypass between April 2008 and October 2012. Patients who were 
randomized to an RIPC stimulus showed similar trends with reduction in perioperative 
myocardial injury by means of reduction in the mean area under the curve for 
concentration of cardiac troponin I. However more importantly they were able to 
demonstrate reductions in 1-year all-cause mortality in the RIPC group. MI rates also 
were reduced, while rates of cardiac death, stroke, and MACCE (postoperative MI and 
TIA or stroke) all showed trends favouring remote preconditioning 135. RIPC in the 
setting of cardiac surgery therefore shows some promise and requires further 
investigation to truly determine whether remote ischaemic preconditioning improves 
clinical outcomes after cardiac surgery. One such trial led by our group is under-way, 
The “ERICCA” trial a multicentre randomised controlled clinical trial, which has now 
recruited nearly 1600 patients, the results of which are hotly anticipated 136. In this 
randomized double-blinded controlled clinical trial circa high-risk patients undergoing 
CABG ± valve surgery using blood cardioplegia are being recruited over a 2-year 
period. Post anaesthetic induction patients will be randomized to receive after either 
RIPC (4 cycles of 5 min inflation to 200 mmHg and 5 min deflation of a blood pressure 
cuff placed on the upper arm) or sham RIPC (4 cycles of simulated inflations and 
deflations of the blood pressure cuff). The primary end points are cardiovascular death, 
non-fatal myocardial infarction, coronary revascularization and stroke at 1 year. 
Secondary endpoints will include peri-operative myocardial and acute kidney injury, 
intensive care unit and hospital stay, inotrope score, left ventricular ejection fraction, 
changes of quality of life and exercise tolerance. The results of this study may provide 
the definitive answer if RIPC can result in the hard end point of improving clinical 
outcomes. 
Elective Percutaneous Coronary Intervention (PCI) or for Acute Myocardial Infarction 
(AMI) 
Iliodromitis and colleagues were the first to investigate RIPC in the context of PCI. The 
study consisted of 41 normotensive patients with stable angina and single-vessel 
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disease undergoing elective PCI of which 20 were given a RIPC protocol of 3 cycles of 
5-minute ischaemia applied to both arms along with 21 controls. Interestingly they 
demonstrated an increase in CK-MB, troponin I, and CRP in the preconditioned group 
91.  Though disappointing, the results of this study must be taken with extreme caution. 
With only 41 patients the study is grossly underpowered to provide a reasonable 
conclusion. The reporting of the study is also misleading. In such a small population it 
would be reasonable to show the individual troponin levels for each participant. This 
would allow the observers to see if there are any erroneously high troponin levels that 
skew the data one way or the other. Secondly on further analysis the study group 
includes a significant number of diabetic patients, who are known to be less responsive 
to preconditioning. Lastly the high use of nitrates, a known cardio-protective mimetic, in 
the control arm may also skew the results in such a small study.  Moving forward, 
Hoole et al in 2009 investigated further in the larger “Cardiac Remote Ischemic 
Preconditioning in Coronary Stenting (CRISP)” study of 242 patients undergoing 
elective PCI. The group demonstrated that RIPC (3 cycles of 5-minute forearm cuff 
inflation to 200 mmHg and deflation) prior to PCI attenuated post procedure cardiac 
troponin I (cTnI) release. Hoole and colleagues were also able to show a reduction in 
the major adverse cardiac and cerebral event rate (MACCE) at 6 months in the RIPC 
group 137. Since this study there have been a number of studies that have consistently 
demonstrated similar reductions in procedural related troponin I release 138,139. Hoole 
and colleagues were interested to confirm if this early benefit in MACCE rate in the 
remote ischaemic-preconditioning group was sustained and had a long-term effect. 
The group have recently published a six-year follow up data of the original cohort. 
89.3% of the original study was available for long-term follow-up with a total of 59 
(30.7%) MACCEs. The group was able to demonstrate patients with a MACCE had 
higher mean cardiac troponin I after PCI, and most interestingly the MACCE rate at 6 
years remained lower in the RIPC group. Hazard ratio was 0.58 at 95% confidence 
interval in the RIPC group and an absolute risk reduction of 0.13. The number needed 
to treat with RIPC to prevent a MACCE at 6 years was only 8 140. This is the first study 
to provide objective evidence that RIPC, a cheap and relatively risk free intervention, 
can have a prognostic benefit in those undergoing elective PCI. Bøtker and colleagues 
investigated the use of RIPC in 333 patients the setting of an acute myocardial 
infarction (AMI). They investigated the potential for use of RIPC as a pre-hospital 
cardio-protective   intervention in patients having an AMI. The RIPC protocol involved 4 
cycles of 5-minute forearm cuff inflation and deflation delivered in the ambulance while 
in transit to hospital. The primary end point was myocardial salvage index at 30 days 
after primary percutaneous coronary intervention measured by myocardial perfusion 
imaging as the proportion of the area at risk salvaged by treatment. Results 
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demonstrate a significant improvement in myocardial salvage index in the RIPC group 
with no differences in major adverse events. In a sub-study of the same patients the 
investigators looked at the short term effects of LV function. The results demonstrate 
no significant overall effect on LV function between RIPC and control groups. However 
improvement in LV function were seen in high-risk patients, those with extensive 
myocardial area at risk (AAR) AAR ≥35% and therefore prone to develop large 
myocardial infarcts 116. Most recently Crimi et al published their study, which sought to 
evaluate whether remote ischemic post-conditioning (RIPostC) could reduce enzymatic 
infarct size in patients with anterior ST-segment elevation myocardial infarction 
undergoing primary percutaneous coronary intervention. 100 patients with anterior ST-
segment elevation myocardial infarction and occluded left anterior descending artery 
were randomized to primary coronary intervention (pPCI) + RIPC (n = 50) or 
conventional pPCI alone (n = 50). RIPC consisted of 3 cycles of 5 min cuff inflation and 
deflation of the lower limb. Promisingly RIPC at the time of pPCI reduced enzymatic 
infarct size measured by CK-MB. The group were able to demonstrate a relative 
reduction of CK-MB release by 20%(confidence interval: 0.2% to 28.7%; p = 0.043).  In 
addition T2-weighted oedema volume 3-5 days post MI, measured through cardiac 
MRI was 37 ± 16 cc in RIPC patients and 47 ± 22 cc in control subjects (p = 0.049). 
Lastly ST-segment resolution >50% was 66% in RIPC and 37% in control subjects 
(p = 0.015).  In addition the patients who had the RIPC stimulus were also associated 
with an improvement of T2-weighted oedema volume and ST-segment resolution 
>50% 
Conclusion 
RIPC has been investigated in other clinical settings such as vascular surgery, cerebral 
and neurological injury, as well as acute kidney injury with mixed results. There are a 
number of confounders that make the translation of laboratory findings on young 
healthy rat hearts to the complexity of the human body. In clinical studies the biggest 
confounders are age, sex, other comorbidities and concomitant drug medications. We 
know from laboratory findings that these all play a role in the ability to protect the heart. 
Older and diabetic hearts are harder to cardio-protect. The patient is often already on a 
cocktail known cardio-protective pharmalogical agents such as metformin, simvastatin 
etc. thus the extent and potential for further cardio-protection is unclear if not small.  
What is clear is that RIPC has the potential to become a valuable adjunct to current 
medical therapy that can help harnesses a powerful innate protective mechanism to aid 
against ischaemic injury. Though the mechanism is yet not fully understood however it 
has shown promise in clinical trials thus far. Large adequately powered studies such as 
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the Effect of Remote Ischaemic preconditioning on clinical outcomes in patients 
undergoing coronary artery bypass graft surgery (ERICCA) will report within the next 2-
3 years that will provide more definitive answers. This hopes to be the definitive 
randomised control trial looking at the effects of RIPC on the hard end points of Major 
Adverse Cardiac and Cerebral Events (MACCE) 12 months after cardiac surgery. The 
results of this trial will prove to be a defining moment in this research field. 
Extracellular Vesicles 
Extracellular vesicles are a heterogeneous population of membrane bound structures 
released by cells in to the extracellular space. Their role in disease and their potential 
for diagnostic and clinical use is under increasing investigation. A consensus 
nomenclature for these heterogeneous vesicles is of yet not fully established. They can 
largely be subdivided in to three main populations exosomes, shedding microvesicles 
and apoptotic bodies.141 
Shedding Microvesicle 
Shedding microvesicles bud directly from the plasma membrane and are then secreted 
directly into the extracellular environment. Although usually larger in size when 
compared to exosomes (30-100nm), shedding vesicles can range from 10nm-1µm in 
size and are more heterogeneous in shape. In contrast to exosomes, which are 
generated via the endosomal pathway, budding from the plasma membrane generates 
shedding microvesicles. In turn the membrane of shedding microvesicles are more 
reflective of their originating cell than the membranes of exosomes.142,143 Studies have 
shown Ca2+ stimulation cells results in an increased secretion of shedding vesicles. The 
mechanisms, which underpin the sorting of protein cargo within shedding 
microvesicles, are not yet understood. Studies thus far have shown a universal 
expression of β1 integrin on the membrane of all shedding vesicles. Platelet shedding 
vesicles contain GPIb and GPIIb–IIIa and P selectin, which are important in 
coagulation. Shedding microvesicles from tumor cells and neutrophils contain 
proteolytic enzymes and metalloproteinases that are thought to play a role in 
inflammation and cancer progression.143 Studies have in addition shown that shedding 
vesicles released from the same cell under rest and stimulation can be molecularly 
distinct from each other.144 Shedding microvesicles have been shown to play a role in 
coagulation, inflammation and tumor progression. They have been shown to induce 
platelet activation and thus play an important role in the pathological process of 
atherosclerosis. Shedding vesicles from platelets and macrophages accumulate in the 
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lipid core of plaques and thrombi promoting further platelet activation and vascular 
dysfunction. 145–147 In contrast, the hypothesis, which was explored in this thesis, is that 
exosomes play a cardio-protective role.  
Apoptotic Vesicles 
Dying and/or apoptotic cells will also release membrane vesicles and are distinct from 
those vesicles released from healthy cells. Apoptotic vesicles, like shedding vesicles, 
bud directly from the plasma membrane and carry a number of nuclear, cytosolic, and 
endoplasmic reticulum (ER)-derived proteins. Apoptotic cells release at least two 
immunologically distinct types of apoptotic vesicles, those originating from the plasma 
membrane contain DNA and histones, whereas apoptotic vesicles originating from the 
endoplasmic reticulum do not but expose immature glycoepitopes148. In general, 
apoptotic vesicles are larger in size when compared to exosomes and shedding 
vesicles. In addition apoptotic vesicles float at a higher sucrose density (1.24-1.28 
g/ml) than exosomes and do not have the exosomal characteristic cup shape 
morphology when visualized by electron microscopy, thus can be visually 
distinguishable from exosomes. Apoptotic vesicles have been reported to have 
immune-activating functions and the inappropriate clearance of apoptotic vesicles is 
considered to be a play a significant role in the development of systemic autoimmune 
disease. Winau et al investigated apoptotic vesicles from mycobacteria-infected 
macrophages. Their results show that apoptotic vesicles from mycobacteria-infected 
macrophages stimulate CD8 T cells in vivo and demonstrated potent adjuvant activity 
by stimulating through Toll-like receptors (TLR). Winau et al, showed that vaccination 
with vesicles from infected cells induced protection against M. tuberculosis infection149. 
The ability of exosomes to transfer genetic content has generated much interest, 
however this ability may extend to apoptotic vesicles as well. Some groups have 
suggested that apoptotic vesicles may play a role in the horizontal transfer of tumor 
DNA to distant sites, which then initiate the genetic transformation leading to tumor 
formation150. 
Exosomes 
Exosomes are lipid bound membranous vesicles that range from 30-100nm in size 151–
153. These intra-luminal vesicles arise from endosomal compartments called 
multivesicular endosomes (MVE). Upon fusion with the plasma membrane, MVE 
release these vesicles in to the extracellular fluid at which point they are referred as 
exosomes. Exosomes have been found secreted by multiple cell lines as well as been 
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found in most bodily fluids including human plasma153,154. There has been more interest 
in exosomes and their possible involvement in health and disease, although originally 
ignored as cell “debris”, their content such as mRNA and miRNA and the ability to 
transfer them are generating interest in the scientific community as a potential novel l 
mode of intercellular communication151,152.  There is currently great interest in the 
potential of both exosomes and microvesicles as therapeutic targets or as biomarkers 
of diverse pathological states including cardiovascular disease, Alzheimer’s disease, 
viral infection, and cancer151,152,155. 
History of Exosomes 
Trams et al. in 1981 first coined the name “exosome” to describe microvesicles that 
were released from neoplastic cell lines156.  Originally MVE, from which exosomes 
arise, were thought to help in the transfer of extracellular molecules to lysosomes for 
degradation. A few years later, however, two independent research groups studying 
reticulocytes described an opposing process157,158. They demonstrated the secretion of 
small vesicles (~50 nm) of endocytic origin by MVEs in cultured reticulocytes. These 
vesicles contained transferrin receptors that had been internalized from the plasma 
membrane158. Sequential electron microscopy images demonstrated a process of 
fusion of the MVEs with the plasma membrane with subsequent release of the 
transferrin containing vesicle outside the cell157. Following their electron microscopy 
findings Johnstone and colleagues were the first to re-isolate these nanovesicles, 
purifying the reticulocyte-culture supernatant by a process of centrifugation. The 
vesicles were then termed “exosomes”
159. 
Research developments in the field of exosomes were fairly sparse for the following 
decade onwards. It was not until 1996 when Raposo et al. rejuvenated interest in this 
field with their paper suggesting these exosomes carry molecules that are involved in 
the adaptive immune response. In this study they showed firstly that EBV – 
transformed B lymphocytes secreted exosomes, and more importantly that these 
vesicles went on to stimulate human CD4 T Cells in an antigen specific manner, 160. In 
1998 the pioneering paper by Zitvogel et al. demonstrated the secretion of exosomes 
from dendritic cells. These dendritic exosomes expressed function major 
histocompatibity Complex class I and II and T-cell co-stimulatory molecules. The study 
also showed the dendritic derived exosomes suppressed growth of murine tumors in a 
T cell dependent manner161. This paper laid the foundation for the hypothesis that 
exosomes could play an integral and distinct role in cell-cell communication and has 
prompted researchers to explore its clinical application. Since then over the years 
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exosome secretion has been described in a multitude of cell lines in addition to the 
above mentioned previously; Hematopoietic cells (B cells, T cells, dendritic cells, mast 
cells and platelets) 160,162–164, neuronal cells 165, Schwann cells166, intestinal epithelial 
cells167, adipocytes168, fibro- blasts169 and tumor cells170, cardiomyocytes171. As 
research within this field has increased the exosomal functions appear to be far more 
complex and each differ in its function dependent on its origin. Exosomes appear to 
work as highly specialized functional extensions of cells. They are largely released in 
biological fluids. To this date exosomes have been isolated from biological fluids such 
as plasma, urine, cerebrospinal fluid and, amniotic fluid and saliva154,172–174. They have 
additionally been isolated from malignant effusions, fluid from bronchoalveolar lavage, 
synovial fluid and even breast milk175–177. This may suggest that exosomes provide a 
mechanism of communication and transfer of material between distant body parts. 
Exosome biogenesis 
The majority of the exosomal proteins discovered to date are found in the cytosol, 
endocytic compartments or plasma membrane. In addition, many of the cytosolic 
proteins found in exosomes are involved in the endocytic pathway178,179. It is for these 
reasons that the current hypothesis is that exosomes have an endosomal origin. 
Exosomes are thought to be formed via endocytic invagination of the plasma 
membrane thus capturing material from the cell cytoplasm 180.  The formation of 
exosomes involves two membrane inversions allowing the retention of similar 
membrane topology as the plasma membrane. The first inversion occurs during 
endocytic internalization and the second inversion occurs as the intraluminal vesicles 
bud off into the lumen of the late endosome 180. Cargos within MVE that are destined 
for lysosomal degradation are ubiquinated. The mechanism that underpins the re-
routing of this MVE for exosomal release is still not yet fully understood. There is some 
evidence to suggest that exosome release may be mediated through endosomal 
sorting complex required for transport (ESCRT) signaling. In particular, a study by 
Thery et al. has shown Alix and Tsg101 to be involved in exosomal secretion in 
dendritic cells. Budding of the intraluminal membrane is thought to be mediated via 
ESCRT-I and ESCRT-II with ESCRT-III responsible for cleaving of the buds to form 
intraluminal vesicles 181. Another model for exosome biogenesis suggests a ceramide 
synthesis driven system 182. GTPases of the Rab family are proteins classically 
responsible for intracellular trafficking183. Evidence suggests that Rab family proteins 
may indeed regulate the targeting of the MVE towards the plasma membrane. In 
human haemopoetic K562 cells, Rab11 has been shown to promote docking and 
fusion of MVBs with the plasma membrane184. Rab27a and Rab27b play important 
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roles in spontaneous secretion of MHC class II-containing exosomes secreted by HeLa 
cells185. The consequent fusion of the exosome with the plasma membrane is then 
thought to be regulated by SNARE proteins 186. Intracellular calcium levels may affect 
exosome release. A study my Merendino et al inhibited exosome secretion through the 
addition of DMA187. And in contrast the addition of monensin, Na+/H+ exchanger that 
results in the accumulation of intracellular calcium to K562 haemopoetic cells, 
markedly enhanced exosome release188. 
 
Figure 4 Diagram describing exosome biogenesis adapted from Raposo et 
al 189. Exosomes formed via endocytic invagination of the plasma 
membrane capturing material from the cell cytoplasm. The first 
inversion occurs during endocytic internalization and the second 
inversion occurs as the intraluminal vesicles bud off into the lumen of 
the late endosome. MVE that are destined for lysosomal degradation 
though some are re-routed resulting in release of exosomes. 
Physical Characteristics & Molecular Composition of Exosomes 
The size of exosomes makes visualization under visual light microscopy not feasible. 
Under electron microscopy exosomes exhibit a specific biconcave or “cup- shaped” 
morphology, although this is believed to be an artifact of drying of the spherical 
vesicles. They differ from the larger shedding microvesicles (sometimes called 
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microparticles) that are also found in plasma, in more than just their size. Shedding 
microvesicles are believed to form by budding off directly from the plasma membrane, 
and appear to have distinct properties from exosomes151,155,164.  
Exosomal cargo can often be donor-cell specific and in addition may be different 
dependent on circumstances of release e.g. oxidative stress. What drives this cargo 
selection within exosomes is still not understood.  
• Protein Composition 
Large-scale proteomic analysis techniques have now allowed exosomal cargo to be 
described in some detail. This proteomic analysis of exosomes has shown common 
characteristic marker proteins on their surface or in their lumen. Typical exosomal 
marker proteins are the heat-shock proteins such as HSP70 and HSP90 and the 
tetraspanins such as CD9, CD63, and CD81. Additionally, exosomes have been 
shown to contain MVE biogenesis molecules such as Alix and TSG101 and 
cytoplasmic proteins such as actin, annexins, and Rab proteins152. These proteins 
may play important roles in disease. Indeed, the relationship between heat shock 
proteins and cardio-protection is well established. Heat shock proteins (including 
αB-crystallin, HSP60 and HSP70) are secreted from cells within exosomes189,190, 
and can be transferred to adjacent cells to confer protection against oxidative 
stress191. Interestingly, circulating HSP70 levels are negatively correlated with 
symptoms of cardiovascular disease192. What is of further interest is that current 
evidence suggests that the exosomal proteome differs according to the type of cell 
that released it 152. This may allow one to determine exosomal origin by the 
expression of typical cellular markers, an example of which is CD31 (PECAM-1) or 
CD62P (P-selectin) found in platelet derived exosomes164. The “Exocarta” database 
provides a useful tool and catalogues the proteins that have been identified in 
exosomes and also the number of studies in which they have been identified193.  
• Lipid Composition 
In addition to proteins exosomes have been shown to contain numerous raft-
associated lipids such as cholesterol and sphingomyelin. The outer surface of 
exosomes has also been shown to contain a number of saccharide groups153,194. 
  
38 
• RNA and microRNA 
The discovery of mRNA and microRNA in 2007 by Jan Lötvall and colleagues was 
a pivotal moment in the field of exosome research. Most interestingly their in vitro 
studies demonstrated not only the presence of exosomal mRNA but that these 
were also functional mRNA. Transfer of mouse exosomal RNA to human mast cells 
lead to the formation of new proteins in the recipient cell195. This landmark 
discovery demonstrates a new form of cell-cell communication. Similarities are 
drawn to viruses where exosomes can “infect” cells with genetic material, which is 
translated to a functional protein. Similarly to the protein cargo, exosomal mRNA 
and miRNA cargo also reflect the cell they originate from, in addition, studies 
indicate that cellular stress can alter exosomal protein and RNA content196.This 
suggests that exosomes may represent a snapshot of the physiological state of the 
cell released into the circulation. The extent to which plasma miRNA is contained 
within exosomes is still controversial. Some studies suggest that exosomes contain 
the majority of plasma miRNA197, while others find plasma miRNAs are mainly in 
argonaute complexes198. However, numerous studies have demonstrated the ability 
of exosomes to transfer miRNA to other cells195,199. Exosomal miRNA and its 
relationship with cardiovascular disease will be discussed later. 
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Figure 5 Diagram describing exosome composition adapted from Thery et al 
180. Encircled by a lipid bilayer containing targeting and adhesion 
molecules, antigen presenting and immunosuppressive molecules. 
Within the exosome there are signal transduction and chaperone 
proteins, membrane trafficking molecules, mRNA and microRNA and 
lastly enzyme peroxidases as well as cytoskeleton molecules. 
  
Function of Exosomes 
The function of exosomes is not yet fully understood. Exosomes are secreted from a 
multitude of cells and it is clear that they affect a vast array of physiological functions, 
dependent on the cell of origin and circumstances at that time.  Exosomes have been 
implicated in having a role in immune suppression and regulation, antigen 
presentation, tumour progression, and inflammation but to name a few. A detailed 
review of the function of exosomes is beyond the scope of this thesis and not 
investigated but the following is a brief summary. 
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• Immune suppression by exosomes 
Interest in exosomes was first ignited by the discovery that exosomes may play a 
role in immune suppression. Thus far the immunological effects that exosomes 
exert play appear to be dependent on the state of the secreting cells. An example 
of which is the secretion of exosomes from dendritic cells. Exosomes secreted from 
mature dendritic cells induce an antigen specific immune response. While dendritic 
cells that have been administered immunosuppressive treatments release 
exosomes that promote immune tolerance200,201. Immune modulation by exosomes 
means that, exosomes are likely to play a significant role in normal growth and 
development. Exosomes from various cell lines contain the death receptor ligand 
Fas ligand (FasL). It is thought that exosomes produced by the trophoblast in early 
pregnancy prevent maternal rejection through FAS mediated T-Cell death202,203. In 
fact pregnant women at term have higher levels of serum FasL associated 
exosomes when compared to with preterm, thus exosomes may play an immune-
suppressive role that helps normal pregnancy. FasL exposing exosomes from 
tumor cells have been shown in vitro to kill Jurkat T cells. It is therefore 
hypothesized that this secretion of FasL containing exosomes from tumor cells 
helps the tumor cells in evading the body’s natural immune system204–206. The exact 
role or contribution to immune suppression by exosomes is still as of yet not fully 
understood. Some studies have shown no immune suppression via exosomes, thus 
the exact role is likely to be model dependent and complex. 
• Antigen Presentation by exosomes 
In addition to immune suppression, there is evidence to suggest exosomes play a 
role in antigen presentation. Exosomes appear to exert diverse effects dependent 
on origin and circumstance thus its role in antigen presentation is likely to be 
complex. Examples include injection of exosomes isolated from allergy tolerant 
mice to naïve mice conferred tolerance to the allergen. Thus, exosomes have the 
ability to prevent allergic sensitization207. In contrast when exosomes purified from 
Bronchoalveolar lavage fluid (BALF) of asthmatic patients were added to airway 
epithelial cells, a pro-inflammatory response of secretion of cytokines was noted. 
Thus exosomes may also contribute to and worsen allergic immune responses.175 
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• Pro tumorigenic effects of exosomes 
The pro tumorinergic effect of exosomes occurs via several mechanisms. Tumour 
derived exosomes have been shown to have significant immunosuppressive 
properties and the immune evasion by tumour cells is a well-established 
mechanism wherein tumours avoid detection and elimination by the host immune 
system. An interesting finding by Abusamra et al. was that tumour derived 
exosomes release of FasL. FasL is important in the transmission of apoptotic 
signals and is lost in cancer cells206. Other evidence for immune suppression by 
tumour-derived exosomes comes from the down modulation of NKG2D due to 
direct exosomal delivery of membrane-bound trans membrane growth factor 
TGFβ1 to CD8+ T cell or NK cell subsets208. In cancer patients, the loss of NKG2D, 
an activating receptor for NK cells, CD8+ T cell and NKT cells, is a critical 
mechanism of cancer immune evasion. However some studies have shown 
tumour-derived exosome also carry antigens that help activate immune cells 
against cancer. It is therefore still unclear whether this contradictory role will result 
in tumour-derived exosomes providing a net pro-tumorigenic or anti-tumorigenic 
role at present. Other groups have suggested that tumour-derived exosomes aid 
tumour progression through the promotion of metastasis to distant sites. An 
interesting study by Hao et al. showed that exosomes could transfer the highly 
metastatic properties from a BI6-10 melanoma tumour cell to a poorly metastatic F1 
melanoma tumour cell. Hao and colleagues injected mice with F1 tumour cells only 
and other mice with F1 tumour cells and exosomes from as well as Bl6–10 
melanoma tumour cells. Those injected with both, F1 tumour cells and exosomes 
from as well as Bl6–10 melanoma tumour cells developed lung metastases, 
compared to the mice injected with F1 tumour cells only, did not 209. Exosomes are 
also thought to promote tumour growth through stimulation of angiogenesis. An 
example of which is seen in mesothelioma cell-derived exosomes. In a study by 
Hegmans et al. mesothelioma cell-derived exosomes were found to have strong 
angiogenic factors that increase vascular development in the region of a tumour210. 
In addition, melanoma-derived exosomes were also capable of stimulating 
endothelial signalling that is important for endothelial angiogenesis211. Further 
evidence of pro-angiogenic role for tumour derived exosomes comes from the 
evidence that exosomes secreted from a pancreatic the line that overexpress 
D6.1A in rats, strongly encouraged tumour growth through systematic induction of 
angiogenesis212. Other mechanisms for pro-tumorinergic role of exosomes include 
the release of active matrix-degrading enzymes, which increase the tumour’s ability 
to invade into the stroma213–215 . Tumour derived exosomes have also been shown 
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to promote tumour growth through modulating stromal cells216. An interesting 
finding from a study by Qu et al. found gastric cancer exosomes have been shown 
to promote cancer cell proliferation through activation of PI3K/Akt and MAPK/ERK 
pathway217. This pathway is of particular interest as it is one of the known cardio-
protective survival pathways discussed previously. 
• Inflammation and exosomes 
The role of exosomes in inflammation like in other areas discussed is complex? 
Dependent on the cell origin and circumstances exosomes can play a pro-
inflammatory role as well as helping suppress it. Exosomal association with known 
pro-inflammatory proteins such as Hsp-70 and TGF-β is well described 189,218. An 
interesting study by Qazi et al. describes pro-inflammatory exosomes in BALF of 
patients with sarcoidosis. The group described increased levels of exosomes in 
BALF from patients with sarcoidosis showed when compared with healthy 
individuals and when incubated with autologous peripheral blood mononuclear cells 
(PBMCs) exosomes from patients with sarcoidosis produced a significantly higher 
interleukin response219. In a study of fibroblast exosomes taken from synovial fluid 
of patients with rheumatoid arthritis, exosomes in the rheumatoid arthritic patients 
contained pro-inflammatory TNF-α that further potentiates the disease through 
delayed activation-induced death of infiltrated T cells220.  
Exosomes in Cardiovascular disease and Cardio-protection 
The role of exosomes in cardiovascular disease is still largely unknown. Some of the 
few groups working on exosomes and its effects in the heart have arrived there 
serendipitously. Lim and colleagues first conceived interest in the field of exosome-
derived cardio-protection through their work on mesenchymal stem cells (MSC)221. 
MSC were originally investigated as potential sources of newly differentiated 
cardiomyocytes when injected into recipient hearts, though this hypothesis has now 
largely been superseded given that few if any new cardiomyocytes have been 
observed. Despite the absence of demonstrable cardiogenesis the injection of stem 
cells has consistently shown improvement of cardiac function and survival. Current 
evidence suggests that MSC actually mediate their cardio-protective properties by 
release of paracrine factors222. Lim SK and colleagues systematically fractionated 
using membranes with different molecular weight cut off to demonstrate complexes 
with a diameter of 50–100 nm mediated the cardio-protective effect and thus 
hypothesized that these complexes were exosomes. The presence of exosomes was 
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then demonstrated by the detection of standard exosomal marker proteins (CD9, 
CD81, Alix), by Western Blotting, typical exosome density determined by sucrose 
density gradient, and observation of the typical “cup” shape by scanning electron 
microscopy. An important criterion is their diameter, which was shown by Nanosight 
Analysis (explained below) of purified fractions to be 100 nm - as expected for 
exosomes221. The exosomes were highly cardio-protective when introduced either into 
Langendorff perfused isolated rat hearts or intravenously into anaesthetized mice 
immediately before reperfusion. Subsequent studies show that cardio-protection by 
conditioned MSC medium requires activation of PI3K/Akt kinases in the protected 
organ223,224. Taking this concept further Chen et al investigated the cardio-protective 
properties of exosomes derived from murine cardiac progenitor cells (CPC). CPC-
exosomes were incubated with H9C2 cardiomyoblasts. Their results demonstrate 
CPC-exosomes protect H9C2 from oxidative stress by inhibiting caspase 3/7 
activation. In addition intra myocardial delivery of CPC-exosomes in an in vivo mouse 
model of myocardial ischemia/reperfusion resulted in a 53% reduction in 
cardiomyocyte apoptosis when compared to PBS control (p < 0.05)225. The most recent 
study by Giricz et al explored a similar hypothesis to that proposed in this thesis, i.e. 
that extra cellular vesicles (EV) might be involved in remote ischaemic preconditioning. 
In their small experiment the group collected coronary effluent from isolated perfused 
rat hearts subjected to 3 × 5 min global ischemia and reperfusion (IPC) or 30 min 
aerobic perfusion. The coronary perfusate with and without EV (removed by differential 
ultracentrifugation) was given to another set of recipient isolated hearts and subjected 
to ischaemia reperfusion protocol of 30 min global ischemia and 120 min reperfusion. 
Their results showed IPC markedly increased EV release from the heart as assessed 
by HSP60. As in preceding studies, perfusate of a preconditioned heart was able to 
attenuate the infarct of a non-preconditioned heart. However, interestingly, this 
protection was lost in the EV depleted perfusate. Though an interesting steps forward 
there are significant limitations to the study. The effluent transfer model from perfused 
hearts is a crude way of inferring a mechanistic role of EV’s in RIPC. Of note, electron 
microscopy characterization of their extracellular vesicles show that the majority of 
vesicles isolated and used in their ischaemia reperfusion protocol were indeed 
>100nm, outside the accepted exosome size226. Though not strictly relating to cardio-
protection, work carried out by Cammusi et al show scientific principles that can be 
translated to the heart for further investigation. Cammusi et al in their study show that 
exosomes/microvesicles released from MSCs reverse acute kidney injury (AKI) by a 
paracrine mechanism by a horizontal transfer of messenger RNA and microRNA. The 
effect of exosome/microvesicle administration in murine models of kidney I/R injury and 
show exosome/microvesicle released from MSCs protect from AKI induced by 
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ischaemia reperfusion injury and from subsequent chronic renal damage. Interestingly 
this effect was obliterated with pretreatment of the exosomes/microvesicles with 
RNAse to inactivate their RNA cargo, suggesting the content of the vesicles playing a 
critical role in their function227,228. 
As a result of reduced coronary blood flow in ischaemic heart disease, collateral 
vessels and microvascular angiogenesis develop as a response to myocardial 
ischaemia over a period of time. It is thought that angiogenesis helps preserve the 
functionality of ischemic myocardium. Therapeutic coronary angiogenesis and 
collateralization have tremendous potential as treatment strategies for patients with 
ischemic heart disease. There is increasing evidence of exosomes having an important 
role in angiogenesis. Cammusi explored this further by showing that EVs promote 
angiogenesis and enhance recovery in a murine model of hind limb 
ischemia through miRNA or mRNA transfer229,230. Further work by Sahoo et al 
shows CD34+ stem cell derived exosomes induce angiogenic activity. Additionally 
HSP20 a protein known to play a role in cardio-protection was shown to be carried by 
exosomes that promotes angiogenesis via activation of vascular endothelial growth 
factor 2 (VEGFR2)231. Deregibus et al show angiogenesis stimulation via means of 
mRNA transfer from exosomes/microvesicles derived from human endothelial 
progenitor cells230. There are numerous further studies showing proangiogenic 
properties of exosomes from multiple cell lines, however many through differing 
mechanisms. In an interesting paper by Leroyer et al, extra cellular vesicles were 
isolated from ischemic muscles and injected into ischemic hind limbs of mice in parallel 
with venous injection of bone marrow-mononuclear cells. Addition of the EVs isolated 
from ischemic mouse hind limbs were shown increase the proangiogenic effect of bone 
marrow-mononuclear cell transplantation232. Exosomes may also play an important role 
in atherosclerosis. Recent work has shown that endothelial and smooth muscle cells, 
which play an important role in atherosclerotic plaque formation, communicate to each 
other via exosomes. Endothelial cells released exosomes enriched with mi-143/145 
were transferred to smooth muscle cells and therefore in a further experiment injected 
of miR-143/145 containing exosomes in a mouse model of atherosclerosis resulted in a 
reduction of atherosclerotic lesion formation199.  
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MicroRNA & IR injury 
MicroRNAs are small (~22 nucleotide RNA sequences) non-coding RNA that regulates 
gene or protein expression, usually by inhibition, through complementary base-pair 
binding with mRNA. There are over a 1000 estimated miRNA genes with over 700 
discovered to this date233. MiRNA have been implicated in both ischaemia reperfusion 
injury and heart failure234. The ability to regulate specific miRNA and their function 
could present a novel cardio-protective strategy.   Several miRNA have been shown to 
be up or down regulated following IR injury thus may play an important mechanistic 
role and target for cardio-protection (Table 1 – adapted from Weiss et al234). The 
potential for clinical application of microRNA both as use as a treatment strategy as 
well as novel biomarkers are just now being explored. Exosomes that carry miRNAs in 
the circulatory system may play a pivotal role. 
Table 1 - Table of microRNA associated with ischaemia 
reperfusion injury adapted from Weiss et al. 
 
Down Regulated Up Regulated 
miR – 21235 miR-21235,236 
miR – 1237 miR-1238,239 
miR- 494240 miR-494240 
miR- 133237 miR-24241 
miR – 320242  
miR-199a243  
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Methods and Materials 
Ethics Approval 
Ethics approval for recruitment of human participants and use of human plasma for 
exosome experimentation was obtained through successful application to the 
Research and Ethics Committee (REC reference: 13/LO/0222) and permission for the 
project was obtained from the University College London Hospital NHS/HSC Research 
and Development department. Please see appendix for full ethics proposal. 
Human Participants 
All participants were recruited after poster advertisement of the project. Each was 
given a research and ethics committee (REC) approved participant information sheet 
detailing the objectives and rational of the project. All participants were given consent 
REC approved consent forms for signature before recruitment into the study.  Inclusion 
criteria and exclusion criteria for recruited participants were as follows: 
Table 2 - Inclusion and exclusion criteria for human participant recruitment. 
 
Inclusion Criteria Exclusion Criteria 
Male, Age <35 Female or Age <18, 
Healthy & free of chronic disease Chronic disease or illness 
Not on any medication On regular medication 
2 
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Exosome Isolation 
The optimal method of exosome isolation, purification and characterization remains 
uncertain and subject to continuing investigation within the exosome scientific 
community. There are currently four main approaches to exosome isolation and 
purification:- 
1. Immune-affinity capture 
2. Size filtration: (series of filters down to 100 nm pore size followed by centrifugation 
to concentrate) 
3. Size exclusion 
4. Ultracentrifugation 
Each has its advantages and disadvantages. Immune–affinity capture has the 
advantage of high specificity yet this comes at as a cost of poor yield. While isolation 
based of size filtration has the advantage of high yield though this often compromises 
quality of sample. Over the years the most generally accepted method for exosome 
isolation appears a process of serial centrifugation followed by ultracentrifugation and 
subsequent density purification (2). At the start of this project few papers had shown a 
consistent method for exosome isolation from particularly from human plasma (1).  
Interestingly in the paper by Caby et al participants donated over half a liter of blood for 
isolation and characterization of exosomes. The challenge for this project lay with 
isolating samples with good purity and yield from significantly smaller blood volumes.   
Blood Sample Collection 
Early morning samples were collected from participants who had fasted from the night 
before and had not performed any strenuous activity that morning. Blood was taken 
from the antecubital vein using BD Vacutainer® stretch latex free tourniquet and a BD 
Vacutainer®Safety-LokTMTMblood collection sets with pre-attached holders. Blood 
was collected directly into a 4.5ml BD Vacutainer® glass plasma tube, blue 
conventional closure (Additive: Citrate solution, 0.5ml; Sodium citrate, 12.35mg; Citric 
acid 2.21mg (Equiv. to 3.2% Sodium citrate)). The blue citrate blood collecting tube 
was used to prevent platelet activation. 
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Figure 6 BD Vacutainer®Safety-LokTMTMblood collection sets with pre-
attached holders. Blood was collected directly into 4.5mL BD 
Vacutainer® glass plasma tube, blue conventional closure. 
 
Differential Centrifugation 
Differential centrifugation allows the isolation of populations cells, organelles or 
vesicles through the ability to separate on the basis of mass.  
To isolate exosomes the blood samples underwent a process of differential 
centrifugation as follows:  
1. Blood was centrifuged at 1,600 x g for 20 min at room temperature to obtain 
plasma. (Platelet activation is less at room temperature than at 4 oC). 
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2. Plasma was then removed and centrifuged at 10,000 x g for 30 min at 4 °C to 
remove cells and platelets. 
                        
 
3. Platelet-free plasma was then transferred to ultracentrifuge tubes for three wash 
steps, first at 100,000 x g for 90 min, 4 °C with a SW-41 rotor and then for two 
further times at 100,000 x g for 60 min at 4 °C. After each ultracentrifuge step, 
supernatant was discarded and pellet re-suspended and washed with PBS.   
                            
 
Remote ischaemic preconditioning protocol 
The established RIPC protocol of 3 cycles of 5 minutes arm cuff inflation followed by 5 
minutes deflation (reperfusion) was used on participants to obtain RIPC exosomes. 
This procedure is well tolerated. Blood was collected from one arm at baseline, then 
the second arm subject to RIPC, and the second blood sample isolated from this arm.  
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Exosome Characterisation 
Electron Microscopy 
Electron Microscopy (EM) was performed in collaboration with Dr Mark Turmaine 
(UCL) for preparation of the electron micrographs. Electron microscopy remains the 
only technique of direct visualization of exosomes. The technique involves the use of 
an electron beam to illuminate the exosomes and produce a magnified image. When 
compared to light microscope, EM has a much greater resolving power and can 
visualize much smaller structures as electrons have wavelengths about 100,000 times 
shorter than visible light photons. Exosomes were isolated as per the protocol above 
however for clearest pictures exosomes were re-suspended in sterile water rather than 
PBS (which tended to crystalize when dried). Electron microscopy was carried out on a 
Joel 1010 transition electron microscope (Joel Ltd, Warwickshire, UK) after a standard 
staining procedure with 0.5% uranyl acetate. 
Protein Assay 
To ascertain the protein yields from exosome isolations the protein content was 
determined using bicinchoninic acid (BCA) protein assay (Sigma, UK) and an 
automated 96-well plate reader (Fluostar Omega, BMG Labtech). The assay works on 
the premise of formation of a Cu2+-protein complex under alkaline conditions, followed 
by reduction of the Cu2+ to Cu1+. The amount of this reduction of the Cu2+ to Cu1+ is 
proportional to the protein present. BCA forms a purple-blue complex with Cu1+ in 
alkaline environments and thus the intensity of the purple-colour is proportional to the 
level of protein in the sample. Exosome samples and samples of bovine serum albumin 
with established protein concentrations (0-2mg/ml protein) were loaded on to a 96 well 
plate. BCA and CuSO4 solution was then added and the plate incubated for 30 min at 
37 ºC with agitation.  FLUOstar Omega microplate reader (BMG Labtech, USA) was 
then used to measure the colour intensity and the exosome sample protein contents 
were quantified by comparison to the normalised curve of BCA colour of the known 
concentrations of BSA samples. All samples were run in duplicate. 
Western Blot Analysis 
Western blot analysis is the most widely used scientific technique of protein analysis of 
a tissue homogenate or extract. The process involves gel electrophoresis to separate 
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proteins according to molecular weight. The proteins are then transferred to a 
membrane and detection of proteins using targeted antibodies. 
Gel Electrophoresis 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was 
conducted using the Mini Protean III system (BioRad, UK) to separate proteins. SDS in 
the sample buffer denatures multimeric proteins and polypeptide chains so that all 
proteins have similar charge:mass ratios. This allows the migration of proteins to be 
determined by size. The addition of an electrical field causes migration of the smaller 
proteins faster down the gel, thus proteins are separated according to molecular 
weight. The polyacrylamide gel used for protein separation was prepared by the 
polymerization of acrylamide and bis-acrylamide. Ammonium per sulfate (APS) and 
tetramethylethylenediamine (TEMED) was added to initiate polymerization. 4 ml of 
resolving gel was poured between two glass plates held in a casting frame. To ensure 
a flat surface 50% isopropanol was pipetted on top of the unset gel. The gel was left for 
10 min to set. Once set the isopropanol was gently poured off. TEMED and APS was 
added to the stacking gel and the stacking gel was then quickly pipetted on to the top 
of the resolving gel with the insertion of a 12 well comb into the stacking gel to provide 
the sample loading wells. The gels were then left to set for 5 min. Once set, the gels 
were placed in a running tank (BioRad, UK) and submerged in running buffer (0.25mM 
Tris-Base, 0.19M glycine, 0.1% SDS) and the combs removed. In the far left well 8µl of 
molecular weight reference marker (BioRad, UK) was then loaded to allow 
determination of protein sizes. Exosome samples were diluted 1:1 with Laemlli buffer 
(BioRad, UK) and heated to 90°C. 20 µl samples were then loaded in to sample wells. 
Gels were run at 180 volts for 1 hour or until separation of the protein ladder and the 
bromophenol blue dye had run off the gel. 
Protein Transfer to Membrane 
Hybond electrochemiluminescence (ECL) (GE Health Care, UK) western blot transfer 
paper was used for the transfer of proteins from the acrylamide gel. Nitrocellulose 
transfer paper and Whatman blotting paper were activated via pre-soaking in 10ml 
100% methanol then 1x transfer buffer: 
• 10% 10x transfer buffer (10x transfer buffer = Glycine 144.2g, Tris 30.3g, in 1litre 
distilled water)  
• 20% MeOH and  
• 70% water.  
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The gels were removed from the glass plates and the stacking gels carefully discarded. 
The gel was then carefully placed on to the activated transfer paper and sandwiched in 
between Whatman blotting paper and loaded on to the transfer tank. The sandwich of 
gel, transfer and blotting paper were further soaked with 1% transfer buffer with air 
bubbles gently removed by rolling a 5ml pipette across the top surface. The gel was 
then set to transfer over 45min at 10V with a current of 1A. 
Membrane Blocking and Protein detection	  
To reduce non-specific binding once protein transfer has taken place, the nitrocellulose 
membrane was blocked for 1 hour with 5% bovine serum albumin (BSA) in PBS–
Tween (PBS Tablets (Sigma, UK) containing: 10mM phosphate buffer, 2.7mM KCl, 
137mM NaCl and 0.1% Tween 20 (Sigma, UK)). The membrane was then washed 
PBS-Tween for 45 minutes. The PBS-Tween was changed every 15 minutes. The 
membrane was then incubated overnight with a horseradish peroxidase (HRP)-primary 
antibody of choice diluted to manufacturer’s guidelines.  The next morning the 
membrane was washed again with PBS-Tween for 45 minutes as per previously 
described. The (HRP) –secondary antibody was then added to the membrane and 
incubated for 1 hour.  The membrane was then washed with PBS tween for 45 minutes 
as per previously described. The membrane was then finally incubated in ECL reagent 
(GE healthcare UK) as per manufacturers protocol, to start the chemiluminescences 
reaction. The incubation of the HRP linked secondary antibody and the ECL agent 
causes the light emitting oxidation of luminol. This light emission was used to detect 
and localize the primary antibody that should be bound specifically to the protein of 
choice on the membrane. After ECL incubation the membrane was sandwiched in 
between Saran wrap and placed in an X-ray film cassette (Kodak, UK) and exposed to 
Hyperfilm ECL high performance chemiluminescence film (GE Healthcare, UK). 
Exposure time was tailored to achieve optimal band intensity and the ECL film is then 
placed in developer followed by fixer solution (Sigma UK). A Black band on the ECL 
film indicates the presence of protein of interest.  Films were left to dry and scanned on 
to the computer. 
Fluorescence-activated cell sorting (FACS) analysis	  
Flow cytometry is a laser-based technique that allows for the counting and sorting of 
cells or particles for experimental purposes, as well as for biomarker detection. 
Particles are suspended in a stream of fluid and passed through a laser. The 
technology allows for the simultaneous measurement of multiple light-based physical 
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characteristics of cells or particles, including intrinsic light emission as well as 
stimulated fluorescence emission. The flow cytometer is composed of three main 
components: 
• Fluidics: that which transports particles/cells through the laser. 
• Optics: a laser, which illuminates the cells and fluorescence detectors. 
• Electronics: which converts the detected light signals into data that can be 
processed by the computer and its dedicated software. 
Flow cytometry then, as a brief summary, allows the analysis of cells or particles in a 
fluid. However, there is a size limitation of this technique, which can only detect 
particles in the range of 0.2 µm to 50 µm. The size of exosomes of 0.05-0.1 µm does 
not allow direct analysis through FACS. To overcome this problem, exosomes were 
conjugated to microspheres (4µm) (Aldehyde/Sulfate Latex Beads, 4% w/v, 4 um 
Molecular Probes), a size that is in the detection range of a flow cytometer. The 
method used to analyze exosomes involved the following five steps: 
1. Nanosight analysis for quantification of exosomes (methods described later) 
Accounting for the size of the microsphere beads, the number of exosomes (50-100 
nm in size) needed to fully coat the beads was estimated to be ~2x109 exosomes. 
Therefore, after Nanosight quantification of each exosome sample, the volume of 
sample needed to coat the microspheres with at least 2x109 exosomes was 
calculated. 
2. Clearing of macromolecular IgG complexes 
The next step was the clearing of macromolecular IgG complexes present in the 
plasma, which are present also in the exosomal samples after purification by 
ultracentrifugation, and they can bind to the microspheres creating the risk of 
unspecific artifacts in the FACS analysis. To overcome this, the exosome sample 
was first cleared of IgGs using G protein sepharose beads. The volume calculated 
from nanosight analysis was then added to PBS solution and 20 µl of G protein 
sepharose beads to make up a 1ml sample. This sample was then rotated at 4°C 
for 60 min and centrifuged 9000 rpm, 4 min, 4°C. The supernatant containing 
cleared exosomes was used for binding to the aldehyde microspheres. 
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3. Binding of exosomes to microsphere beads. 
The next step is the binding and conjugation of exosomes to microspheres beads, 
whose size ranges inside the detection limits of the FACS. Following the previous 
centrifugation, the supernatant (cleared exosomes) was taken into a new tube and 
5 µl of aldehyde beads (Aldehyde/Sulfate Latex Beads, 4% w/v, 4um Molecular 
ProbesR)) were added. This was then incubated for 1 h at 4°C with rotation for 
binding of the exosomes to the microspheres. Once incubated the sample was then 
centrifuged at 9000 rpm, 4 min, 4°C. The supernatant was removed and 1ml PBS 
added. Centrifugation and removal of supernatant was repeated a further two times 
as washing steps. 
4. Binding to Primary and Secondary antibodies 
The exosome-coated microspheres were re-suspended and blocked in 1 ml of 1% 
BSA/PBS 0.1% NaN3 (blocking buffer). This was then left to rotate at 4°C for 1 
hour. 100 µl aliquots of the blocked beads were then transferred into new tubes. 
These aliquots were then incubated with different primary antibodies for 1 h at 4°C 
for the detection of specific markers. The microsphere beads that had been stained 
with primary antibody were washed three times through a process of centrifugation 
at 9000 rpm, 4 min, 4°C in blocking buffer. After the third wash the samples were 
re-suspend in 100 µl blocking buffer and incubated with the appropriate fluorescent 
secondary antibodies for 40 min at 4°C (Anti-Rabbit Alexa 488/ Anti-Mouse Alexa 
488). Once incubated with the secondary antibody, the exosome-coated beads 
were washed 3 times by centrifugation and finally re-suspended in 100 µl blocking 
buffer, working in a dark environment to prevent fluorescence photo-bleaching. The 
optimal dilutions for all antibodies were titrated, after a series of experiments with 
different titers of primary and secondary antibodies. 
5. Analysis on the Flow Cytometer 
The microsphere beads were then analyzed on a flow cytometer (Accuri C6, BD 
Biosciences) using the software Cflview PlusAnalysis (BD Biosciences). Each 
aliquot was aspirated into the flow cytometer and results were presented 
graphically. From the initial forward scatter vs. side scatter plot (FSC/SSC), the 
population of beads was gated. A second graph of pulse width vs. SSC plot allowed 
the gating of singlet’s of beads. A third plot showed the specific fluorescence of 
each set of beads, according to the different antibodies used. Results were 
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presented as histogram plots, against control experiments using beads that were 
blocked with BSA, in the absence of exosomes. On each experiment, control 
samples with no exosomes were used. 
    
            A        B 
Figure 7 A) Accuri C6, BD Biosciences flow cytometer. B) Diagram depicting 
Aldehyde/Sulfate Latex Beads with bound exosomes and primary 
and secondary antibody. 
 
Nanoparticle Tracking Analysis 
For many years a reliable methodology of exosome quantification had not been 
developed and accepted. At the start of this project a new apparatus called the 
“Nanosight” a nanoparticle tracking analysis (NTA) machine had entered the market. 
Its manufacturers claimed the ability to accurately visualize and quantify particles in 
liquids from 10-2000nm.  NTA analysis is based on the principle that the rate of 
Brownian movement of nanoparticles in a solution is related to their size. When 
illuminated by a 405nm laser the scattering of light by the particles is measured using a 
microspore and scientific digital camera. Software produced specifically tracks each 
particle and using the Stokes-Einstein equation the rate of particle movement is related 
to a size/sphere diameter of the particle. The technique thus allows for the calculation 
of number of particles in a given solution and the distribution of particles in relation to 
size of particles. Exosome samples were diluted in 1ml PBS to achieve optimal 
concentration for nanosight analysis as per manufacturers guidelines based on visual 
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interpretation of the number of particles on viewing screen. If the sample was too 
concentrated the nanosight’s ability produce accurate results was affected. From this, 
the particle concentration of the original sample was calculated. The diluted sample 
was then injected into sample chamber of the Nanosight LM10 unit (Nanosight Ltd, 
Amesbury, UK) while holding the chamber vertically ensuring that no air bubbles were 
present. The 430nm laser was then switched on and visual parameters were optimized 
as per manufacturer’s guidelines. The rest of the sample (in 1ml syringe) was placed 
on the electronic syringe set to start continuous slow injection of sample through the 
chamber. Three 30-second videos were recorded for each sample and analyzed by the 
Nanoparticle Tracking Analysis (NTA) 2.2 software. After each sample analysis the 
chamber was dismantled was cleaned thoroughly with 70% ethanol and dried before 
the insertion of the next sample. 
 
            A        B 
Figure 8 A) Photograph of nanosight LM10 unit. B) Nanosight microscope 
unit uses a laser light source to illuminate particles within a 0.3 ml 
sample, introduced to the viewing unit with a disposable syringe. 
Particles appear individually as point-scatterers moving under 
Brownian motion, which are then visualized on a computer screen 
and quantified using the nanosight software provided. Diagram 
taken from www.Nanosight.com 
 
MicroRNA isolation and Analysis (collaboration with Centre of 
Cardiovascular Genetics, UCL. Professor Steve Humphries and Anastasia 
Z. Kalea) 
The immediate research group within the Hatter institute did not have the expertise in 
miRNA isolation and analysis thus collaborations were formed with the Centre of 
Cardiovascular Genetics at UCL working with Professor Steve Humphries and 
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Anastasia Z. Kalea. Human plasma exosomes were isolated as per isolation protocol 
described previously in this thesis at the Hatter Institute. After various optimization 
experiments human plasma exosomes, isolated by ultracentrifugation, were finally re-
suspended directly in miRVana homogenization buffer to improve quality and yield of 
RNA. miRNA isolation was carried out at the Centre of Cardiovascular Genetics using 
the miRVana kit (Ambion, Austin, TX, USA). The RNA was further purified with 4 
ethanol washes and RNA pellet re-suspended in 20 µl of distilled H2O. Finally RNA was 
purified further with DNAse I treatment. miR expression measurements were carried 
out using real time-PCR. 
Ischaemia Reperfusion Invitro Methods 
Primary cardiomyocyte isolation (Carried out by Jose Vincencio, Hatter 
Cardiovascular Institute) 
Male Sprague Dawley rats (aged circa 4 months) were used in these studies and were 
obtained from Charles River UK. Animals were treated in accordance with the Animals 
(Scientific Procedures) act 1986 published by the UK Home Office and the Guide for 
the Care and Use of Laboratory Animals published by the US National Institutes of 
Health (Publication No. 85-23, revised 1996). Rats were anesthetized with 300 µl of 
intra peritoneal sodium pentobarbital. The hearts of adult rats were isolated, placed in 
an ice-cold buffer and perfused via the aorta on a non-recirculating perfusion 
apparatus. Perfusate used was a modified calcium-free Krebs-Ringer-HEPES (KRH) 
buffer (in mM): 116.0 NaCl, 5.4 KCl, 0.4 MgSO4, 20.0 HEPES, 0.9 Na2HPO4, and 5.6 
glucose (pH7.4). The hearts were perfused at 14ml/min for 5 minutes with KRH buffer 
containing 1 mg/ml BSA and 3.3 µM EGTA. The perfusate was bubbled with 100% 
oxygen with the temperature maintained at 37°C. The isolated rat hearts were then 
perfused for 15minutes with Worthingtontpe II collagenase and 25 µM calcium. Lastly 
the isolated hearts were perfused with KRH buffer containing 50µM calcium for 5 min. 
The hearts were then dismounted from the perfusion apparatus. The atria were first 
trimmed away leaving the ventricles to be then minced. The ventricles then underwent 
a series of further digestions with collagenase and then filtered through a nylon mesh. 
Finally the cells were washed with restoration buffer: KRH buffer plus 10 mg/ml BSA, 
0.5 mM Na-pyruvate, 5.0 mM taurine, 2.0 mM carnitine, 1.0 mM creatine, and 75 µM 
calcium. Cells were then placed onto laminin coated round coverslips and incubated 
overnight at 37°C in an atmosphere of 95% air-5% CO2 in M-199 medium (M7653, 
Sigma) containing 10% fetal calf serum and 1% penicillin-streptomycin (Sigma). The 
following day, cells were washed and kept in restoration buffer.  
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In vitro Ischaemia Reperfusion Testing (Carried out in conjunction with Jose 
Vincencio and Jessica Kearney, Hatter Cardiovascular Institute) 
Ischemia and reperfusion was simulated by firstly placing the cardiomyocyte cells in an 
ischaemic buffer containing 128 mmol/L NaCl, 2.2 mmol/L NaHCO3, 14.8 mmol/L KCl, 
1.2 mmol/L MgSO4, 1.2 mmol/L K2HPO4, 1 mmol/L CaCl2, 10 mmol/L Na. lactate (pH 
6.4). The cardiomyocyte cells were then placed in a hypoxic chamber in which the air 
was replaced 95% N2/ 5% CO2 for 3 h. Post 3 hours the cardiomyocyte cells were 
removed and placed into a standard incubator in normal medium. For controls, 
cardiomyocyte cells were incubated in normoxic medium containing 118 mmol/L NaCl, 
22 mmol/L NaHCO3, 2.6 mmol/L KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L K2HPO4, 1 
mmol/L CaCl2, 10mmol/L glucose (pH 7.4 gassed with 95% O2 / 5% CO2). The five 
different groups tested were: 
1. Control cardiomyocytes placed in normoxic buffer 
2. Cardiomyocytes + Ischaemia Reperfusion 
3. Cardiomyocytes + Ischaemia Reperfusion + Control Human Plasma Exosomes 
(concentrations of 0.5µl to 0.0005µl) 
4. Cardiomyocytes + Ischaemia Reperfusion + RIPC Human Plasma Exosomes 
(concentrations of 0.5µl to 0.0005µl) 
5. Cardiomyocytes + Ischaemia Reperfusion + Insulin  
Cardiomyocytes cells were then analyzed under the microscope and the percentage of 
cell death was calculated.  
    
                            A             B 
Figure 9 Image of A) largely dead myocytes (red dots) and B) Healthy (alive) 
myocytes. 
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CHAPTER 
 
Results 
Isolation technique and characterisation 
of Exosomes 
Introduction 
The optimal method of exosome isolation, purification and characterization remains 
uncertain and subject to continuing investigation. Exosome isolation using 
commercially available polymeric precipitation kit, Exoquick was briefly assessed. 
However, based on the most widely accepted, current recommendations differential 
centrifugation was chosen as the method for exosome isolation from human plasma 
and evaluated in the following experiments244.  
Aims 
The aim for these experiments was: 
1. To characterize and confirm the presence of exosomes isolated by the method of 
differential centrifugation using established methods: 
 
a. Electron microscopy 
b. Protein and Western Blot Analysis 
c. Nanoparticle tracking analysis (to establish validity and use as a tool for 
quantification of exosomes) 
3 
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d. Flow cytometry 
 
2. To optimise the isolation technique for exosomes from human plasma and 
determine optimum storage conditions for future experiments. 
 
3. Establish the presence of, and isolate microRNA from human plasma exosomes.
  
Results 
To characterize and confirm the presence of exosomes isolated by the method of 
differential centrifugation using established methods:- 
Electron Microscopy 
Detailed Methods 
Early morning blood samples were collected from participants who had fasted from the 
night before and had not performed any strenuous activity that morning. Blood was 
taken from the antecubital vein using BD Vacutainer® stretch latex free tourniquet and 
a BD Vacutainer®Safety-LokTMTMblood collection sets with pre-attached holders. A 
total of 72ml Blood was collected directly into a 4.5ml BD Vacutainer® glass plasma 
tube, blue conventional closure (Additive: Citrate solution, 0.5ml; Sodium citrate, 
12.35mg; Citric acid 2.21mg (Equiv. to 3.2% Sodium citrate)). 16 x 4.5mL BD 
Vacutainer® glass plasma tubes containing blood was then centrifuged at 
1,600 x g for 20 min at room temperature to obtain plasma.  The plasma was then 
removed and placed in 2ml eppendorf tubes and centrifuged at 10,000 x g for 30 min at 
4 °C to remove cells and platelets. Platelet-free plasma then transferred to 
ultracentrifuge tubes for three wash steps, first at 100,000 x g for 90 min, 4 °C with a 
SW-41 rotor and then for two further times at 100,000 x g for 60 min at 4 °C. After each 
ultracentrifuge step, supernatant was discarded and pellet re-suspended and washed 
with water.  Electron microscopy was carried out on a Joel 1010 transition electron 
microscope (Joel Ltd, Warwickshire, UK) after a standard staining procedure with 0.5% 
uranyl acetate. Electron Microscopy (EM) was performed in collaboration with Dr Mark 
Turmaine (UCL) for preparation of the electron micrographs. 
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Result 
By electron micrography of the exosome preparations, we observed the classical 
concave “cup shaped vesicles” within the expected size range (50-100nm) of 
exosomes (Fig 10).   
 
Figure 10 Successful isolation of exosomes from human plasma through 
differential centrifugation as evidenced by electron microscopy. 
Electron micrographs of purified human plasma exosomes. Bar 100 
nm. 
 
Discussion 
The presence of cup shaped vesicles by electron microscopy (Fig 10), of the expected 
size range (50-100nm diameter), confirms successful isolation of exosomes from 
human plasma through the protocol of differential centrifugation. Although the vesicles 
are believed to be spherical in solution, they have the appearance of collapsed vesicles 
after drying. 
Western Blot Analysis of exosomal proteins 
As per convention we also sought to confirm successful exosome isolation by the 
presence of known exosomal protein markers using western blotting. For future 
experiments it was also important to ascertain a protocol for exosome isolation that 
would produce a relatively pure sample, with the trade-off that the yield remain 
62 
reasonably high. The amount of exosomal protein in human plasma is likely to be 
dwarfed by the abundance of other serum proteins. Albumin is the most abundant 
blood protein, and thus one of the potential contaminants. Using human albumin as a 
marker of serum protein and a surrogate marker for impurity, serial ultracentrifuge 
washing steps were carried out to identify the number of washes needed to obtain the 
cleanest sample while still acquiring adequate protein concentrations for further 
experimentation.  
Specific Aims 
1. To ascertain the number of ultracentrifuge washes that produces the purest sample 
of exosome while retaining enough protein for analysis. 
2. To confirm that the isolation technique produce exosomes as evidenced by known 
markers of exosomes on western blot analysis 
Ascertain the number of ultracentrifuge washes that produce the purest sample of 
exosome while retaining enough protein for analysis. 
Detailed Methods 
Exosome isolation 
Exosomes were isolated from 54ml of human blood (12 x 4.5mL BD Vacutainer glass 
plasma tubes) as described above (electron microscopy experiment) up until the 
ultracentrifugation step. After centrifugation to produce platelet free plasma, this is then 
transferred to 6 ultracentrifuge tubes (4ml plasma per tube) and made up to 8ml with 
sterile PBS for wash steps at 100,000 x g for 90 min, 4 °C with a SW-41 rotor. After the 
first wash step one tube removed, supernatant discarded and pellet re-suspended in 
1ml PBS. Sample labelled as Sample 1. The supernatants of the five remaining tubes 
were discarded and the pellet re-suspended in 8ml PBS and put forward for a further 
ultracentrifuge wash. This process was repeated for further 4 ultracentrifuge washes at 
100,000 x g for 60 min at 4 °C. After each ultracentrifuge step one tube removed, 
supernatant discarded and pellet re-suspended in 200µl PBS. Resulting in 5 samples 
ranging from 1 ultracentrifuge wash to 5. (1 extra sample was kept through the process 
in case of any errors/spillages)   
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Protein Assay protocol 
Exosome samples were aliquoted into a 96 well plate, and compared with a serial 
dilution of standard protein concentrations (0-2mg/ml protein) obtained using bovine 
serum albumin.  Bicinchoninic acid (BCA) protein assay reagent (Thermo Scientific) 
and CuSO4 solution was then added and the plate incubated for 30 min at 37 ºC with 
agitation. This assay is based on the principle that protein will chelate copper ions 
(biuret reaction), reducing Cu2+ to Cu1+, which reacts with bicinchoninic acid forming an 
intense purple-coloured reaction product. A FLUOstar Omega microplate reader (BMG 
Labtech, USA) was then used to measure the light absorbance at wavelength 562 nm. 
Exosome sample protein contents were quantified by comparison to the normalised 
curve of BCA colour of the known concentrations of BSA samples. All samples were 
run in duplicate. 
SDS-PAGE Sodium-dodecylsulphate (SDS) polyacrylamide gel electrophoresis 
(PAGE) Western blot experiment protocol 
Exosome sample preparation 
For Sample 1, 20 µl Exosome sample taken and added to 180 µl of Laemlli buffer 
(Sigma, bromophenol blue 0.004%, DTT 400 mM, glycerol 20%, SDS 4%, TRIS, 
0.125 M), in a 1.5 ml Eppendorff. Samples 2-5, 100 µl Exosome samples taken and 
added to 100µl of Laemlli buffer in a 1.5 ml Eppendorf tube. All were then boiled at 95 
oC for 10 min to fully denature the proteins, and finally centrifuged at 12,000 rpm for 
5mins. Samples were then ready for loading on to the gels. 
Gel Preparation 
10% polyacrylamide resolving gels were made by mixing 3.75 ml of 1 M Tris-HCl pH 
8.8 with 3.34 ml 30% Acrylamide, 2.8 ml distilled H2O and finally 100 µl of 10% SDS in 
a 50 ml Falcon tube. 7.5 µl of TEMED and 75 µl APS mixed together then added to the 
gel mixture just prior to pouring between glass gel plates to give the gels a thickness of 
0.75 mm. Approximately 4 ml of resolving gel was added between each set of plates, 
giving a gap of ~0.5 cm between the top of the resolving gel and the bottom of the 
wells in the stacking gel. Butanol was gently pipetted on to the unset resolving gel to 
ensure it set flat. After the resolving gel had set, the butanol was removed Stacking gel 
made up by mixing 0.625 ml 1 M Tris-HCl pH 6.8 with 0.75 ml 30% Acrylamide, 3.5 ml 
Water and 50µl 10% SDS in a 10 ml Falcon tube. Similarly 7.5µl TEMED and 75µl APS 
were added to the stacking gel, before it too was poured between the plates. 12-well 
combs were placed into the stacking gel to ensuring loading of samples could occur. 
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Gels were immersed in running buffer (0.25mM Tris-Base, 0.19 M glycine, 0.1 % SDS). 
20 µl Exosome samples and 7 µl of molecular weight markers (BioRad, UK) were 
loaded on to the stacking gel. Applying 180 V separated proteins electrophoretically 
across the gel until the bromophenol blue dye had run through the gel (~ 1 h).  
Protein transfer 
Proteins were then transferred onto PVDF membranes (Amersham, UK) pre-wetted in 
methanol and equilibrated in transfer buffer (25 mM Tris-base, 0.19 M gylcine, 20 % v-
v methanol, 0.1 % w-v SDS). Resolving gels were placed on top of PVDF membranes 
and sandwiched between 2 pieces of blotting paper (also pre-soaked in transfer buffer) 
and placed in a semidry transfer cell (BioRad, UK). Air bubbles were removed by 
rolling a disposable serological pipette across the preparation before transferring at 10 
V for 45 min with the current limited at 250 mA per gel. 
Zinc Stain 
PVDF membrane added to Pierce Zinc Reversible Stain for 10 min then remove. Zinc 
developer solution added to membrane for two minutes then removed. 10 ml sterile 
water added. To erase the stain, Zinc Stain eraser solution was added and left to rock 
for 5 minutes. Membrane then washed 3 x 5 min with 10 ml sterile water. 
Membrane Blocking and Incubation with Human Albumin antibody:  
PVDF Membrane blocked with 5 % Bovine Serum Albumin (BSA) PBS      solution 1 h. 
Membrane then incubated in 1:1000 anti-albumin antibody ab19194 (Cell Signalling) 
with gentle rocking overnight in cool environment. Membrane then washed 3 x 15 min 
with PBS-0.1% Tween. Rabbit anti-albumin antibody (Cell signaling) was then added 
and incubated for 1 h with gentle rocking. The secondary antibody was then discarded 
and the membrane washed again 3 x 15 min with PBS-0.1%Tween. 
Western Blot Analysis 
The membranes were analyzed on a Li-Cor Odyssey infrared fluorescent imaging 
system. 
Results 
We observed a decreasing yield of protein with increasing numbers of 
ultracentrifugation steps (Table 3, Fig 11). 
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Table 3 - Table of calculated protein yield (µg) per 1 ml plasma from isolation 
samples using differing number of ultracentrifugation wash steps. 
 
Number of ultracentrifuge steps Protein Yield (µg) per 1 ml plasma 
1 969.7 
2 35.4 
3 14.3 
4 3.8 
5 1.5 
 
 
 
 
Figure 11 Graphical bar chart representation of calculated protein yield (µg) 
per 1 ml plasma from isolation samples using differing number of 
ultracentrifugation wash steps. 
To determine albumin content the protein was separated by SDS-PAGE and albumin 
content measured by Western blot analysis. We observed a decreasing albumin signal 
with increasing number of ultracentrifugation washes. 
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Figure 12 Comparison of purity of human exosome preparations from 4 ml 
plasma using 1-5 ultracentrifuge steps. A) Zinc stain B) Anti-
albumin western blot. 
 
Discussion 
From the above experiments we conclude that 3 ultracentrifuge washing steps with 
PBS produces a sufficient pure exosome sample from human plasma while 
maintaining enough exosomal concentration for further analysis. 
Does isolation technique of exosomes from human plasma produce exosomes as 
evidenced by known markers of exosomes on western blot analysis? 
Detailed methods 
Human Exosome Isolation 
Exosomes were isolated from 81ml of human blood (18 x 4.5mL BD Vacutainer glass 
plasma tubes) as described previously up until the ultracentrifugation step. Platelet free 
plasma was then transferred to 6 ultracentrifuge tubes (6ml plasma per tube) and 
centrifuged at 100,000 x g for 90 min, 4°C with a SW-41 rotor. The supernatant was 
discarded leaving ~ 10µl and then re-suspend in 8 ml PBS. A further ultracentrifuge 
wash step was undertaken at 100,000 g 60 min, 4°C in Beckman Optima L in SW-41 
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for 1 hr. The supernatant was discarded leaving ~ 10µl and re-suspend in 8 ml PBS. 
The final ultracentrifuge wash step was undertaken at 100,000 g 60 min, 4°C in 
Beckman Optima L in SW-41 for 1 hr. Exosome pellets (non–visible) were re-
suspended in 500µl sterile from 6 centrifuge tubes and combined to form 1 sample 
SDS-PAGE Sodium-dodecylsulphate (SDS) polyacrylamide gel electrophoresis 
(PAGE) Western blot experiment protocol: 
Exosome sample preparation 
A 100µl Exosome sample was taken and added to 100µl of Laemlli buffer 1.5ml 
Eppendorff tube and boiled at 95°C for 10 min.  The sample was then centrifuged at 
12,000 rpm for 5 min and loaded on to gels. 
Gel Preparation & Transfer 
Gel preparation and protein transfer to membranes was carried out as described 
previously. 
Membrane Blocking and Incubation with Primary and Secondary antibodies 
The same experimental protocol was carried out as per previously described. The 
classical exosomal protein markers HSP70, CD63, CD9 and CD81 were probed using 
following antibodies and corresponding secondary antibodies: 
1. HSP70 (Santa Cruz) 1:200; 1:500 Mouse Secondary Antibody 
2. CD63   (Santa Cruz); 1:200; 1:500 Rabbit Secondary Antibody  
3. CD9     (Santa Cruz); 1:200; 1:500 Mouse Secondary Antibody 
4. CD81   (Santa Cruz); 1:200; 1:500 Rabbit Secondary Antibody 
ECL protocol and scientific film development 
7 ml GE Healthcare Western Lightning® Chemiluminescence Reagent was added to 
PVDF Membrane and incubated for 3 min at room temperature with gentle shaking. 
The Western blot was taken to the developing room and the membrane placed 
between the covers of a propylene sheet protector with the black interface removed. 
The lights were switched off and Kodak Scientific Imaging film placed on top of the 
membrane. The film was exposed for various amounts of time for optimum detection 
and then developed. 
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Results 
To confirm isolation of exosomes the protein content of isolation samples were 
separated by SDS-PAGE and classical protein markers for exosomes content 
measured by Western blot analysis. We were able to detect two of the classical 
exosomal protein markers HSP70 and CD63, however CD9 and CD81 were 
consistently undetectable (Table 4, Figure 13).  
Table 4 - Table of common exosomal proteins probed in our human plasma 
exosomes via western blot. HSP70 and CD63 detected though CD9 and CD81 not 
detected. 
Protein Marker detected? 
HSP70 Yes 
CD63 Yes 
CD9 No 
CD81 No 
 
Figure 13 Western blot of human plasma exosomes showing detection 
HSP70 and CD63. 
  
69 
Discussion 
HSP70 and CD63 were consistently found in exosomes from the plasma from all 
participants. Interestingly though classically in literature the molecular weight of CD63 
in exosomes is described as 53 kDa. We consistently detected a signal at 26 kDa both 
in human plasma exosomes but also in concurrent work carried out on rat plasma 
exosomes. On further review of the antibody product data sheet, it describes the 
molecular weight of CD63 core protein as 26 kDa. The other typical tetraspanins 
tested, CD9 and CD81 were consistently undetectable in our samples. This again was 
consistent with the findings of other experiments within our group working on rat 
plasma exosomes. It is interesting to note the first study by Marie-Pierre Caby et al 
who demonstrated the presence of these tetraspanins in human plasma through 
western blotting, isolated exosomes from a far greater sample of blood (600ml as 
compared to our 81ml)154, our limiting factor being the size of centrifugation systems. 
This inability to detect these tetraspanins may be due to insufficient protein 
concentration or a lack of sensitivity of our primary antibodies. Alternatively, the exact 
complement of tetraspanin molecules may vary between exosomes of different 
sources, and CD9 and CD81 may not be present at high concentration in plasma 
exosomes. We thus conclude through the detection of classical exosomal protein 
markers HSP70 and CD63 that our isolation protocol successfully isolates exosomes 
from human plasma. 
Exoquick vs Ultracentrifugation method for exosome isolation 
A number of easy-to-use and inexpensive commercial kits are also available for 
exosome isolation such as ExoQuickTM (System Biosystems). The exact methods by 
which these kits isolate exosomes are not disclosed by their respective companies, but 
involve selective precipitation by a proprietary polymer. Here we briefly assessed their 
ability to isolate exosomes and purity.  
Detailed methods 
Human Exosome Isolation 
Ultracentrifugation exosomes were isolated using 3 ultracentrifugation washes while 
Exoquick exosomes were isolated as per manufactures protocol and guidelines245 
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Results 
Both Exoquick and Ultracentrfugation methods successfully isolate human plasma 
exosomes based on westernblot analysis for known exosome markers HSP70 and 
CD63. However Exoquick samples appear less pure when probed for human abumin, 
 
Figure 14 Western blot of human plasma exosomes showing detection 
of HSP70 and CD63 and anti-albumin through 
ultracentrifugation (UC) and Exoquick (System Biosystems) 
isolation. 
 
Discussion 
Our pilot study shows that both Exoquick and Ultracentrifugation methods successfully 
isolate human plasma exosomes based on western blot analysis for known exosome 
markers HSP70 and CD63. However the purity appears to be low. This concurs with 
increasing reservation of this isolation technique within the scientific community 246 .  
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Nanosight Tracking Analysis 
As described previously the Nanosight tracking analysis (NTA) equipment is currently 
the only established method of visualising and quantifying exosomes in a polydisperse 
sample.  In the following experiments the NTA equipment was used to confirm the 
successful isolation plasma exosomes. Secondly, using the NTA equipment we aimed 
to establish the variability in exosome numbers produced from our isolation technique. 
The variability in exosome numbers produced from the protocol of analysing by NTA 
was also calculated. This provided confidence that we had established a reliable and 
reproducible method of exosome isolation from human plasma. Lastly while working 
with limited resources of human samples as well as the time consuming protocol for 
isolation, it was important to establish the optimal storage conditions for exosomes that 
would allow for future experiments. 
Specific aims 
 
1. Does isolation protocol produce exosomes as per detected by NTA? 
2. Using the NTA analysis machine, calculate the variability in numbers of exosomes 
isolated from our isolation protocol from human plasma. In addition calculate the 
internal variability of the NTA machine analysis protocol. 
3. Using the Nanosight NTA, what is the optimal storage condition of exosomes for 
future analysis and experiment use? 
Does isolation protocol produce exosomes as per detected by the Nanosight? 
Detailed Methods 
Human Exosome Isolation 
Three participants were recruited to participate in this experiment. Human plasma 
exosomes were isolated using the same protocol used in the previous experiment. 
Resulting in 3 exosome samples from 3 participants: Labelled 1 to 3. 
Analysis on Nanosight 
10µl of exosome samples were diluted in 1ml PBS to achieve optimal concentration for 
nanosight analysis as per manufacturers guidelines based on visual interpretation of 
the number of particles on viewing screen. The diluted exosome sample was then 
injected into sample chamber of the Nanosight LM10 unit (Nanosight Ltd, Amesbury, 
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UK) while holding the chamber vertically ensuring that no air bubbles were present. 
The 430nm laser was then switched on and visual parameters were optimized as per 
manufacturer’s guidelines.  The rest of the sample (in 1ml syringe) was placed on the 
electronic syringe set to start continuous slow injection of sample through the chamber. 
Three 30-second videos were recorded for each sample and analysed by the 
Nanoparticle Tracking Analysis (NTA) 2.2 software. After each sample analysis the 
chamber was dismantled was cleaned thoroughly with 70% ethanol and dried before 
the insertion of the next sample. Results were then analysed to calculate number of 
particles isolated per ml/plasma. Sterile PBS buffer alone was analysed to ensure 
those particles that were seen were indeed from the exosome isolation sample alone. 
Results 
 
I analysed the isolation samples from 3 participants using the Nanosight NTA system. 
We were able to demonstrate that our isolation sample had staggeringly large particle 
concentrations with an average of 2.4 x 1011 particles per ml human plasma. The modal 
sizes of these particles (85-96nm) were also in the exosomal size range (Table 5, 
Figure 14). 
Table 5 -  Table  of  NTA  analysis  results  from the human plasma exosome 
isolations  from  3  participants  showing  the  calculated  concentration   of 
particles/ml  of  plasma  and  their  modal  size. Sterile buffer alone shows no 
particles thus all particles are true reflection of sample selection.  
Participant Concentration (particles/ml plasma) Modal Size (nm) 
Sterile PBS buffer 0 0 
1 2.22E+11 96 
2 2.13E+11 85 
3 2.90E+11 88 
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A 
  
B 
 
Figure 15  A. Graphical bar chart representation of NTA analysis results from 
the human plasma exosome isolations from 3 participants showing 
the calculated concentration of particles/ml of plasma and their 
modal size. B. Nanosight still image of moving particle 
 
Discussion 
From our results we can see that in all three participants our isolation technique 
produces on average 2.4 x 1011   particles per ml plasma. The modal size of particles 
ranged from 88-96nm in size. This is within the expected size range of exosomes. 
Additionally sterile buffer alone shows no particles thus all particles seen are a true 
reflection of sample isolation. We therefore conclude that our isolation technique 
successfully isolates exosomes from human plasma as evidenced by visually 
consistent particles on the NTA machine. Of interest, our NTA analysis results show 
the presence of some larger particles in our sample, though in much smaller numbers. 
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These larger particles may be microvesicles, plasma proteins, or potentially other 
subcellular organelles. A potential limitation of NTA is that it is unable to distinguish 
vesicles from other similarly sized particles, but when our NTA data is taken in 
combination with EM and western blotting results, it strongly indicates the presence of 
high quantities of exosomes. 
What is the variability in numbers of exosomes isolated from our isolation protocol from 
human plasma? In addition calculate the internal variability of the NTA machine 
analysis protocol. 
Detailed methods 
Human Exosome Isolation 
Exosomes were isolated from 81ml of human bloods (18 x 4.5mL BD Vacutainer glass 
plasma tubes) as described previously up until the final ultracentrifugation step. After 
the third ultracentrifuge wash step the supernatants from each centrifuge tubes are 
discarded for final time. Pellets re-suspended in 500 µl sterile PBS from 2 centrifuge 
tubes and combined to form 1 sample – labelled “Sample 1”. Pellets from the next 2 
centrifuge tubes were re-suspended in 500 µl sterile PBS and combined to form 1 
sample – labelled “Sample 2”. Pellets from the final 2 centrifuge tubes were re-
suspended in 500 µl sterile PBS and combined to form 1 sample – labelled “Sample 3”. 
The result was 3-exosome samples label 1 to 3. 
Nanosight Analysis 
To test internal variability of the NTA machine analysis protocol 3 x10µl of exosome 
sample 1 were diluted in 1ml PBS to give 3 dilution samples. These samples were then 
analysed on the NTA machine as described in the detailed methods in previous 
experiment. To test the variability in numbers of exosomes isolated from our isolation 
protocol from human plasma, 10µ from each exosome sample labelled 1-3 was diluted 
in 1ml sterile PBS and then analysed on the NTA machine as described in the detailed 
methods in in previous experiment. 
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Results 
Three sample dilutions created as per NTA analysis protocol, resulted in particles 
concentrations of 4.7 x 108, 4.86 x 108 and 4.93 x 108 particles/ml of sample. The 
results show a variability coefficient of 2.4% for the NTA analysis. (Table 6, Figure 15). 
Variation in NTA machine analysis protocol 
Table 6 - Table of NTA analysis results from 3 identical dilutions from the same 
sample of human plasma exosomes (as per NTA analysis protocol) to calculate 
the variability coefficient of the NTA analysis protocol. These results show a 
variability coefficient of 2.4% for the NTA analysis. 
Dilution Concentration (particles /ml of sample) 
Standard 
Error 
Modal 
Size 
Standard 
Error 
1 4.7E+8 0.12 73.8 1.5 
2 4.86E+8 0.26 76.3 1.2 
3 4.93E+8 0.11 98.0 3 
 
 
Figure 16 Graphical bar chart representation of NTA analysis results from 3 
identical dilutions from the same sample of human plasma 
exosomes (as per NTA analysis protocol) to calculate the 
variability coefficient of the NTA analysis protocol. These results 
show a variability coefficient of 2.4% for the NTA analysis. 
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Variation in Exosome Isolation 
3 human plasma exosomes samples were isolated from the same person at the same. 
We observed Nanosight results showing particle concentrations of 4.93 x 108, 4.57 x 
108, 5.43 x 108 per ml of sample. This results in a variability coefficient of 8.6% for the 
human plasma exosome isolation protocol.  
Table 7 - Table of NTA analysis results from 3 human plasma exosomes samples 
taken and isolated from the same person at the same to calculate the variability 
coefficient of the human plasma exosome isolation protocol. These results show 
a variability coefficient of 8.6%. 
Sample Concentration (particles/ml of sample) 
Standard 
Error 
Modal 
Size 
Standard 
Error 
Sample 1 4.93E+8 0.11 98 3 
Sample 2 4.57E+8 0.17 88.8 8.65 
Sample 3 5.43E+8 0.24 78.4 1.03 
 
 
Figure 17 Graphical bar chart representation of NTA analysis results from 3 
human plasma exosomes samples taken and isolated from the 
same person at the same to calculate the variability coefficient of 
the human plasma exosome isolation protocol. These results show 
a variability coefficient of 8.6%. 
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Discussion 
Inter-sample variation on taking dilutions for nanosight analysis was within acceptable 
limits with a variability coefficient of 2.4%. In addition our exosome isolation protocol 
produced reproducible results within acceptable limits with exosome sample variability 
coefficient of 8.6%. Typically, coefficients of variation <10% are regarded as being 
acceptable for assaying variation in clinical samples, thus our assay procedure is 
acceptable for obtaining reproducible data. 
Using the Nanosight what was the optimal storage conditions of exosomes for future 
analysis and experiment use? 
Detailed Method 
Samples 1-3 from previous experiment analysed on day 0 as per previous results then 
split into two. One sample stored at 4°C and one sample stored at -80°C. Both 4°C and 
-80°C samples then re-analysed 5 days later on the nanosight to see optimal storage 
conditions. 
Results 
Three human plasma exosomes samples analysed on day 1 then at day 4 with 
samples being stored at 4 °C and -80 °C to ascertain optimal storage conditions. 
Results show storing exosome samples at -80 °C appears to maintain exosome 
concentrations. (Table 8, Figure 17). 
Table 8 - Table of NTA analysis results from three human plasma exosomes 
sample analysed on day one then at day 4 with samples being stored at 4 °C and 
-80 °C to ascertain optimal storage conditions. Results show storing exosome 
samples at -80 °C appears to maintain exosome concentrations. 
Sample Day 0 (particles/ml x10E8) 
4 °C (particles/ml 
x10E8) 
-80 °C (particles/ml 
x10E8) 
1 4.93 1.78 4.12 
2 4.57 1.65 3.75 
3 5.43 2.11 5.17 
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Figure 18  Graphical bar chart representation of NTA analysis results from 
three human plasma exosomes sample analysed on day one then 
at day 4 with samples being stored at 4 °C and -80 °C to ascertain 
optimal storage conditions. Results show storing exosome 
samples at -80 °C appears to maintain exosome concentrations. 
 
Discussion 
From the following experiment we conclude the optimal storage conditions for exosome 
samples were at -80°C, which was consistent with other literature findings244. 
Fluorescence-activated cell sorting (FACS) analysis	  
Though now confidant that our isolation protocol indeed isolated exosomes from 
human plasma. We were additionally keen to assess the viability to analyze exosomes 
through flow cytometric analysis. As evident from our western blotting experiments, 
protein and biomarker detection in exosomes themselves can be problematic due to 
the low protein yield and the probable lack of sensitivity of primary antibodies. Although 
flow cytometry is incapable of directly detecting particles of less than ~300 um 
including exosomes, an alternative approach is to adsorb exosomes onto small, latex, 
microsphere beads. This can make biomarker detection easier and thus provide 
another tool in exosomal analysis. In principle this technique should only detect 
biomarkers and proteins that lie on the surface of exosomes, so can also provide 
information as to the location of proteins. In the following experiment we therefore 
aimed to determine a protocol for human plasma exosome analysis by flow cytometry 
Da
y 0
4 D
eg
ree
s
-80
 De
gre
es
0
2
4
6
M
ea
n 
pa
rti
cl
es
 /m
l  x
 E
8 Day 0
4 Degrees
-80 Degrees
79 
and to further confirm the presence of exosomes through our isolation technique 
through the detection of the known exosomal proteins CD63, HSP70, CD9, CD81. 
Specific aims 
1. Determine a protocol for human plasma exosome analysis through FACs analysis  
2. Confirm the presence of exosomes through our isolation technique through the 
detection of the known exosomal proteins CD63, HSP70, CD9, CD81 
Determine a protocol for human plasma exosome analysis through FACs analysis  
Detailed methods 
Human Exosome Isolation 
Human plasma exosomes were isolated using the same protocol used in experiment 
3.1.2.2. 
FACS analysis protocol 
Exosome samples were analysed on NTA analysis machine as per detailed protocol in 
previous experiments to calculate number of exosome per ml of sample. After 
Nanosight quantification of each exosome sample, the volume of sample needed to 
coat the microspheres with at least 2x109 exosomes was calculated. Exosome samples 
were then cleared of macromolecular IgG complexes. The volume calculated from 
Nanosight analysis (previous step) was then added to PBS solution and 20 µl of G 
protein sepharose beads (which binds IgG), to make up a 1ml sample. This sample 
was then rotated at 4 °C for 60 min and centrifuged 9000 rpm, 4 min, 4 °C. The 
supernatant containing cleared exosomes was used for binding to the latex aldehyde 
microspheres. Cleared exosomes were taken into a new tube and 5µl of aldehyde 
beads (Aldehyde/Sulphate Latex Beads, 4% w/v, 4µm Molecular Probes)) were added 
then incubated for 1 h at 4 °C with rotation for binding of the exosomes to the 
microspheres.  The sample was then centrifuged at 9000 rpm, 4 min, 4 °C. The 
supernatant was removed and 1ml PBS added. Centrifugation and removal of 
supernatant was repeated a further two times as washing steps. The exosome-coated 
microspheres were re-suspended and blocked in 1 ml of 1% BSA/PBS + 0.1% NaN3 
(blocking buffer). This was then left to rotate at 4 °C for 1 hour.  100µl aliquots of the 
blocked beads were then transferred into new tubes. These aliquots were then 
incubated with different primary antibodies for 1 h at 4°C for the detection of specific 
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markers: 1:100 (HSP70, CD63, CD9, CD 81). The microsphere beads, stained with 
primary antibody, were washed three times through a process of centrifugation at 9000 
rpm, 4 min, 4 °C in blocking buffer. After the third wash the samples were re-suspend 
in 100µl blocking buffer and incubated with the appropriate fluorescent secondary 
antibodies for 40 min at 4°C  
• HSP70 (1:200 Anti-Mouse Alexa 488). 
• CD63   (1:200 Anti-Rabbit Alexa 488). 
• CD9     (1:200 Anti-Mouse Alexa 488). 
• CD 81  (1:200 Anti-Rabbit Alexa 488). 
Once incubated with the secondary antibody, the exosome-coated beads were washed 
3 times by centrifugation and finally re-suspended in 100µl blocking buffer, working in a 
dark environment to prevent fluorescence photo bleaching. The optimal dilutions for all 
antibodies were titrated, after a series of experiments with different titres of primary and 
secondary antibodies. The microsphere beads were then analysed on a flow cytometer 
(Accuri C6, BD Biosciences) using the software Cflview PlusAnalysis (BD Biosciences).  
Each aliquot was aspirated into the flow cytometer and results were presented 
graphically. Results were presented as histogram plots, against control experiments 
using beads that were blocked with BSA, in the absence of exosomes. On each 
experiment, control samples with no exosomes were used. 
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Results 
The results of flow cytometry analysis of human plasma exosomes show the detection 
of classical exosomal proteins CD63, CD81, CD9 and HSP70. (Figure 18) 
A  
B 
 
Figure 19 Flow cytometry analysis of human plasma exosomes. Beads alone 
as well as beads with exosomes and secondary antibody show no 
increase in signal. The subsequent results show the detection of 
classical exosomal proteins CD63, CD81, CD9 and HSP70. “FL1-A” 
indicates fluorescence channel 1, in which fluorescence of the 
secondary antibody was detected. “Count” on the x-axis represented the 
number of beads detected with that fluorescence intensity. The same 
sample was stained with the primary antibody indicated (red curve), or 
secondary antibody alone (“2ary”, black). 
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Discussion 
 
From the following experiment we demonstrate a viable protocol of exosomal 
biomarker and protein content analysis via flow cytometry. We were able to further 
confirm the successful isolation of human plasma exosomes from our protocol by the 
detection of the classical exosomal proteins CD63, CD9, HSP70 and CD81. Even the 
tetraspanin proteins, CD9 and CD81 that were not detectable via western blotting were 
detected by our flow cytometry analysis. These results therefore support our 
hypothesis that flow cytometric analysis may be a more sensitive method for biomarker 
analysis of human plasma exosomes - certainly for those biomarkers or proteins that 
reside on the surface of the exosome.  
MicroRNA analysis 
Establish the presence of, and isolate microRNA from human plasma exosomes.  
The extent to which plasma miRNA is contained within exosomes is still controversial. 
Some studies suggest that exosomes contain the majority of plasma miRNA197, while 
others find plasma miRNAs are mainly in argonaute complexes 198. However, 
numerous studies have demonstrated the ability of exosomes to transfer miRNA to 
other cells195,199 and miRNA have been implicated in both ischaemia reperfusion injury 
and heart failure(ref). The ability to regulate specific miRNA and their function could 
present a novel cardio-protective strategy.   The optimal isolation method of miRNA 
from human plasma exosomes is yet to be established. We aimed to establish an 
isolation protocol for miRNA from human plasma exosomes and explore their potential 
role in cardio-protection in RIPC.  
Specific aims 
1. Isolate miRNA from human plasma exosomes. 
Detailed Methods 
Human plasma exosomes were isolated 72ml blood from recruited participants as per 
previously described and exosome pellets re-suspended in the initial experiments 
500µl PBS. After various optimization experiments human plasma exosomes, isolated 
by ultracentrifugation, were finally re-suspended directly in 250µl miRVana 
homogenization buffer to improve quality and yield of RNA.  miRNA isolation was 
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carried out at the Centre of Cardiovascular Genetics and thus is described briefly for 
the purpose of this thesis. miRNA isolation was carried out using the miRVana kit 
(Ambion, Austin, TX, USA). The RNA was further purified with 4 ethanol washes and 
RNA pellet re-suspended in 20 µl of distilled H2O. Finally RNA was purified further with 
DNAse I treatment. miRNA expression measurements were carried out using real time-
PCR.  
Expression levels for miR-16, snoU6 and RNU6B were first tested for. miR16 has been 
described as a surrogate marker of bulk exosome release247. snoU6, a small nucleolar 
“guide” RNA molecule that primarily guides chemical modifications of other RNAs. 
Lastly  RNU6B is a small nucleolar RNA and common normalization control for miR 
expression. These two endogenous reference RNA’s were used to normalize the 
amount of target miRNA (miR-16). In addition GAPDH, an mRNA known to be 
expressed in exosomes195 was quantified with a view to using its expression on 
exosomes as an alternative-normalizing gene. This was carried out using a High 
Capacity RNA-to-cDNA kit. Ubiquitin C expression was tested to measure for relative 
expression.  Runs were conducted at 40 cycles and 1µg OD cDNA was used for each 
20 µl reaction. Reactions were performed in triplicates. 
Results 
We observed a miR signal from human plasma exosome samples for miR-16, snoU6, 
Ubiquitin C and GAPDH. RNU6B was not expressed at all in our samples.  Results 
show SnoU6 as a better normalization control for our human exosome samples and 
thus this was used as a reference to calculate 2−ΔΔCt for miR16 and GAPDH. (Table 9 
Figure 19) 
Table 9 - Table of Average Ct readings (relative measure of the concentration of 
target in   the PCR reaction) for miR-16, RNsnoU6, RNU6B, GAPDH and Ubiquitin 
C.  2−ΔΔCt compared to RNsno16 were also calculated for miR-16 and GAPDH. 
miRNA Average Ct Average 2−ΔΔCt compared to RNsno16 
miR-16 29.08 1.025 
RNsnoU6 35.58 NA 
RNU6B NA NA 
GAPDH 34.01 1.028 
UBC 36.24 NA 
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Figure 20 Graph of 2−ΔΔCt compared to RNsno16 for miR-16 and GAPDH. 
 
 
Discussion 
Though in small quantities we were able to successfully isolate microRNA from our 
human plasma exosome samples. We observed signals from human plasma exosome 
samples for miR-16, snoU6 and GAPDH. UBC was expressed at close enough levels 
to be used as normalization control for GAPDH. SnoU6 is a better normalization control 
for our human exosome samples while RNU6B was not expressed at all in our 
samples. These results provide a protocol for further microRNA experiments on human 
plasma exosomes. Experiments comparing the microRNA content of RIPC and control 
exosomes can now be carried out.  
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CHAPTER 
 
Results 
A comparison of RIPC and Control 
Exosomes 
Introduction 
As discussed earlier the mechanism of cardio-protection conferred through remote 
ischaemic preconditioning is not fully understood. Humoral factors are proposed to play 
a key role, yet the identification of the precise humoral factors have been challenging. 
Indeed it may be several humoral factors working in conjunction that lead to the cardio-
protection seen through RIPC.  In the following experiments we look to see what the 
effect of remote ischaemic preconditioning has on human plasma exosomes, both in 
terms of their quantity as well as content.  
Specific Aims 
1. Compare and quantify exosomes from human plasma taken after remote ischaemic 
preconditioning (RIPC exosomes) with exosomes taken from normal human 
plasma (control exosomes) by Nanosight analysis 
2. Compare the protein content of RIPC exosomes with control exosomes by Western 
Blot analysis.  
3. Compare the protein content of RIPC exosomes with control exosomes by flow 
cytometry analysis. 
4. Compare the miRNA content of RIPC exosomes and Control exosomes 
4 
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Results 
Compare and quantify exosomes from human plasma taken after remote 
ischaemic preconditioning (RIPC exosomes) with exosomes taken from 
normal human plasma (control exosomes) by Nanosight analysis 
Detailed Methods: 
• Exosome Isolation 
6 participants were recruited into this experiment. Each participant had 72ml of 
human bloods (16x 4.5mL BD Vacutainer glass plasma tubes) before (control 
blood) and after a RIPC stimulus of 3 cycles of 5 minutes arm cuff inflation followed 
by 5 minutes deflation (RIPC blood). Exosomes were then isolated from control 
blood and RIPC blood as described previously up until the ultracentrifugation steps 
while ensuring both are kept separate. 3 x10ml of control human platelet free 
plasma put in 3 ultracentrifuge tubes and similarly 3 x10ml of RIPC human platelet 
free plasma put in the last 3 ultracentrifuge tubes. The plasma is then centrifuged at 
100,000 x g for 90 min, 4 °C with a SW-41 rotor. The supernatant is discarded 
leaving ~ 10µl and then re-suspend in 8 ml PBS. (Ensuring different pipettes used 
for control and RIPC samples). A further ultracentrifuge wash step undertaken at 
100,000 g 60 min, 4 °C in Beckman Optima L in SW-41 for 1 hr. Supernatant 
discarded leaving ~ 10µl and re-suspend in 8 ml PBS. Last ultracentrifuge wash 
step undertaken at 100,000 g 60 min, 4 °C in Beckman Optima L in SW-41 for 1 hr. 
Exosome pellets (non–visible) from the 3 control ultracentrifuge tubes were re-
suspended in 1ml sterile PBS combined to form 1 control exosome sample. 
Exosome pellets from the 3 RIPC ultracentrifuge tubes were re-suspended in 1ml 
sterile PBS combined to form 1 RIPC exosome sample. Each exosome Control and 
RIPC exosomes, divided into 100µl aliquots, labelled and stored at -80°C for 
storage for further experiments. 
• Nanosight analysis 
Both control and RIPC exosomes were analysed on the Nanosight using the 
methods described in previous experiments. Participants 4 and 5 had to be diluted 
further to 1:400 and 1:200 concentrations respectively to comply with nanosight 
manufacturer recommendations of particles per screen for optimal analysis.   
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Results 
We observed in all 6 participants a significant rise in exosome concentration (Table 10 
Figure 20): 
Table 10 - Table of NTA analysis results from 6 human plasma exosomes 
samples pre and post RIPC. Participant 4 and 5’s exosome samples had to have 
further dilutions (1:400 and 1:200) as compared to the other samples (1:100) to 
achieve NTA software recommendation recommendations for number of 
particles on the screen to achieve optimal analysis. Results show in each 
participant a rise in exosome numbers after RIPC.   
Participant 
Control Exosomes  
(particles/ml 
sample x10E8) 
Standard 
Deviation 
RIPC Exosomes  
(particles/ml sample 
x10E8 
Standard 
Deviation 
1 3.64 0.46 4.87 0.46 
2 2.87 0.30 3.36 0.18 
3 2.59 0.41 7.78 0.72 
4 (1:400) 7.25 0.38 12.99 2.14 
5 (1:200) 2.39 0.43 9.25 0.80 
6 3.41 0.46 5.26 0.51 
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Figure 21 Graphical bar chart representation of NTA analysis: A. Results 
from 6 human plasma exosomes samples pre and post RIPC. 
Participant 4 and 5’s exosome samples had to have further dilutions 
(1:400 and 1:200) as compared to the other samples (1:100) to achieve 
NTA software recommendations for number of particles on the screen to 
achieve optimal analysis. B. Pooled analysis of all participants. Results 
show a significant rise in exosome numbers (P=0.02 two tailed) after 
RIPC. 
 
Discussion: 
The results show interestingly that remote ischaemic preconditioning of three cycles of 
forearm cuff inflation and deflation lead to a rise in plasma exosome concentration. 
This is seen consistently through all the participants. This trend is also seen in the 
parallel rat exosome experiments carried out within our research group. The rise in 
exosome concentration may indicate a role for exosomes in the cardio protection that 
is conferred through RIPC. 
At what time point do exosomes concentration rise post RIPC stimulus? 
As discussed previously, current convention for the remote ischaemic preconditioning 
stimulus stands at 3 cycles of 5 minutes forearm cuff inflation followed by 5 minutes of 
forearm cuff deflation. Though there have been no studies to date that confirm this as 
89 
the optimal RIPC protocol. We carried out a small experiment to gauge at which time 
point resulted in the corresponding rise in exosome concentrations seen previously.  
Detailed Methods: 
3 participants were recruited; each participant had 9ml of human bloods (2x 4.5mL BD 
Vacutainer glass plasma tubes) taken before (control blood) the RIPC stimulus. Then a 
further 9ml of human blood 30 seconds after the last of 3 RIPC cuff inflations, then 
finally a further 9ml of human blood 5 minutes after the final RIPC cuff inflation. 
Exosomes where then isolated as per previously described from 4ml of plasma per 
group (Control, 30 seconds post RIPC and 5 minutes post RIPC). Exosomes were then 
analysed on the NTA analysis machine as per previously described protocol. 
Results: 
Peak rise in exosome concentrations occur only after the last 5 minutes of cuff 
deflation (reperfusion) in the 3 cycles of RIPC protocol. (Table 11, Figure 21) 
Table 11 - Exosome Concentrations at different time points (control, 30 seconds 
post RIPC and 5 minutes post RIPC). Exosomes isolated from 4ml plasma and 
pellet suspended in 1ml PBS. 1:100 dilutions taken for nanosight analysis. 
 
PARTICIPANT CONTROL 30 SECS POST 
RIPC 
5MINS POST RIPC 
 CONC 
(particles/ml) 
SD CONC 
(particles/ml) 
SD CONC 
(particles/ml) 
SD 
Participant 1 2.80E+08 0.13 4.09E+08 1.09 8.54E+08 0.64 
Participant 2 5.40E+08 0.22 6.11E+08 0.54 6.76E+08 0.41 
Participant 3 3.55E+08 0.31 4.68E+08 0.21 1.10E+09 0.32 
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Figure 22 Exosome Concentrations at different time points (control, 30 
seconds post RIPC and 5 minutes post RIPC). Exosomes isolated 
from 4ml plasma and pellet suspended in 1ml PBS. 1:100 dilutions 
taken for nanosight analysis. Results suggest the peak rise in 
exosome concentrations occur only after the last 5 minutes of cuff 
deflation (reperfusion) in the 3 cycles of RIPC. 
 
Discussion 
Our results suggest a peak rise in exosome concentrations occur only after the last 5 
minutes of cuff deflation (reperfusion) in the 3 cycles of RIPC protocol. These results 
may provide support to the convention of using 3 cycles of 5 minutes of cuff inflation 
and deflation. Though beyond the scope of this project further experiments should be 
conducted to ascertain the precise point of rise in exosome concentration following 
RIPC. Could indeed one cycle 5 minutes of cuff inflation and deflation be enough to 
produce a similar response? It would also be interesting to determine the response in 
human plasma exosome concentration to further cycles of RIPC.  
Compare the HSP70 and CD63 content in RIPC exosomes with control 
exosomes by Western Blot analysis 
Though confident that RIPC produced a rise in human plasma exosome concentration 
from our NTA analysis it was important to confirm an increased presence of exosomes 
in our RIPC samples when compared to our control and not other particles such as 
apoptotic bodies. We therefore took each participant RIPC and control samples from 
experiment 4.1.1 and analysed and compared the concentrations of HSP70 and CD63. 
If indeed RIPC produced a greater concentration of human plasma exosomes therefore 
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one would expect a greater concentration of exosomal protein markers HSP70 and 
CD63 in the RIPC sample 
Detailed Methods: 
The 6 RIPC and Control human exosome samples from experiment 4.1.1 were used 
for this experiment. For each sample the protein concentration from the extraction and 
thus protein concentration per ml of each sample was ascertained using the protein 
assay protocol used in experiment 3.1.2. The protein assay results were then used to 
calculate the volume of sample need to load equal protein concentrations of RIPC and 
control sample on to SDS PAGE western blot gels.  Participant 4’s samples were not 
put forward for further analysis for fears of impurity given the large protein 
concentration when compare to the other samples. Exosome sample preparation and 
western blot analysis was carried out using the same protocol as previously described. 
Samples were probed for HSP70 and CD63. Density of bands were then analysed to 
quantify signals using Image J software. 
Results: 
Here we detail the protein concentrations of each RIPC and control exosome isolation 
sample from all 6 participants. Of note we observe large amount of protein in 
participant 4’s control sample when compared to the other samples. This raises the 
possibility of impurity and thus this participant’s samples not taken forward for western 
blotting. 
Table 12 - Table of protein concentration (µg/ml) of exosome isolation samples, 
RIPC and Control from the 6 participants.  Note large amount of protein in 
participant 4’s control sample when compared to the other samples, thus not 
taken forward for western blotting for fear of impurity. 
Participant Protein from total control extraction 
(µg/ml) sample 
Protein from total RIPC 
extraction (µg/ml) sample 
1 287.86 328.36 
2 98.45 124.62 
3 69.16 108.42 
4  2767.72 883.53 
5  651.12 527.13 
6 586.32 699.72 
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Our western blot analysis demonstrates demonstrate greater concentration of HSP70 
and CD63 consistently in the RIPC samples when compared to the corresponding 
control sample. (Figure 22) 
 
Figure 23 Western blot analysis of HSP70 and CD63 for comparison between 
human RIPC and control exosome samples in 4 participants 
(P1:P4). A. Participant 1 (P1) taken forward for quantification. 
Results demonstrate greater concentration of HSP70 and CD63 
consistently in the RIPC samples. B. Raw data for all participants 
shown. 
 
Discussion: 
Our results show that RIPC human plasma exosome samples contain more HSP70 
and CD63 than control human plasma exosomes. This therefore confirms our NTA 
analysis findings that RIPC increases circulating human plasma exosome 
concentrations. This raises the question whether this rise in exosomes may play a role 
in the cardio protection conferred by RIPC. 
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Compare RIPC exosomes with control exosomes by Western Blot analysis 
for known cardio-protective signalling proteins 
The pro-survival protein kinases of the RISK pathway have been shown to confer 
cardio-protection against ischaemia reperfusion injury 48. RIPC has also been shown to 
protect via the RISK pathway5,9,248. Traditionally these pro-survival kinases are 
activated through G protein coupled receptors (GPCR), however we tested the 
hypothesis that human plasma exosomes, particularly RIPC exosomes, may contain 
these active kinases and therefore confer cardio protection directly when released in to 
the cell.  
Detailed Methods 
Further human participants were recruited for exosome isolation. All participants 
underwent RIPC protocol and exosome isolation protocol as described previously. 
Human exosome samples, both RIPC and control were analysed through SDS PAGE 
western blot analysis as previously described. RIPC and exosome samples were 
probed for the following pro-survival protein kinases of the RISK: P13K, MEK 1/2, AKT, 
ERK1/2 using their primary antibodies (1:100 concentration) 
Results: 
Our results show that western blot analysis on RIPC and Control human plasma 
exosomes did not detect the presence of known pro-survival kinases of the RISK 
pathway. (Table 13) 
Table 13 - Table showing the results of western blots analysis of human RIPC 
and control plasma exosomes for known pro-survival kinases P13K, MEK 1/2, 
AKT, ERK1/2. Pro-survival kinases were not detected in our RIPC and control 
human plasma exosomes. 
Pro-survival kinase Detected in Control Exosomes? 
Detected in RIPC 
Exosomes? 
P13K No No 
MEK ½ No No 
AKT No No 
ERK ½ No No 
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Discussion: 
Despite multiple attempts, we could not demonstrate the presence of pro-survival 
kinases directly in human plasma control or RIPC exosomes. This may simply be a 
limitation of working with samples that contain such a small amount of protein. 
However if the result is true, and indeed pro-survival kinases are not directly located in 
human plasma exosomes (especially RIPC exosomes), there may be other signalling 
proteins or growth factors within human plasma exosomes that may work at a higher 
level in the RISK pathway, and directly on the GPCR. Indeed HSP70 itself has been 
shown to have cardio-protective properties249–251, however this protein is seen in both 
RIPC and control exosomes. This could possibly explain a mechanism for cardio-
protection through plasma exosomes in general, however would not explain an 
exosomal mechanism for the cardio-protection conferred through RIPC as HSP70 is 
seen in both RIPC and control exosomes 
Compare RIPC exosomes with control exosomes by flow cytometry for 
known cardio-protective signalling proteins 
As described previously our experiments suggest flow cytometry may provide a more 
sensitive tool for the detection of biomarkers in exosomes. We therefore used FAC’s 
analysis method to attempt to detect the same pro survival kinases P13K, MEK 1/2, 
AKT, ERK1/2 in our RIPC and control exosomes. 
Detailed Methods: 
The RIPC and control human plasma exosome samples isolated in the previous 
experiment were also used in this experiment. FACS analysis was carried out using the 
protocol as described previously using the same concentrations for primary (1:100) and 
secondary antibody (1:200). 
Results 
Our results show that FACS analysis on RIPC and Control human plasma exosomes 
did not detect the presence of known pro-survival kinases of the RISK pathway. (Table 
14) 
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Table 14 - Table showing the results of FACS analysis of human RIPC and 
control plasma exosomes for known pro-survival kinases P13K, MEK 1/2, AKT, 
ERK1/2. Pro-survival kinases were not detected in our RIPC and control human 
plasma exosomes. 
Pro-survival kinase Detected in Control Exosomes? 
Detected in RIPC 
Exosomes? 
P13K No No 
MEK ½ No No 
AKT No No 
ERK ½ No No 
 
Discussion: 
We could not demonstrate the presence of pro-survival kinases on the surface of 
human plasma control or RIPC exosomes through FACS analysis.  
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CHAPTER 
 
Are human RIPCS plasma exosomes 
cardio-protective against ischaemia 
reperfusion injury? 
Introduction 
A role for exosomes in cardio-protection has not been fully established though as 
described previously, preliminary work by various groups implicate that exosomes from 
various cell lines indeed may have some involvement in cardio-protection. In this 
experiment we hypothesis that the cardio-protection conferred through RIPC is 
mediated through circulating plasma exosomes. We therefore tested the hypothesis 
that circulating RIPC plasma exosomes will confer cardio-protection in an invitro model 
of ischaemia reperfusion injury while control plasma exosomes will not.  
Aims 
Establish if RIPC exosomes are cardio-protective in a an in-vitro model of ischaemia 
reperfusion injury using rat cardiomyocyte cells 
Methods 
The detailed methods for this experiment are described in the methods and material 
chapter. The experiment was carried out in collaboration with Jose Vincencio and 
Jessica Kearney from the Hatter Cardiovascular Institute, who helped with the rat 
myocyte isolation and in-vitro simulated ischaemia reperfusion testing.  
5 
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Results 
Our model of simulated ischaemia reperfusion was confirmed to work with an increase 
in cardiomyocyte cell death from 13 ± 3% to 59 ± 7% (n=5, P<0.001). Both the addition 
of 5 µl of RIPC exosomes or control exosomes at reperfusion conferred significant 
cardio-protection and reduced cardiomyocyte cell death to 17 ± 3% and 17 ± 4% 
respectively. A dose response experiment was undertaken with the addition of serial 
dilutions of RIPC and control exosomes at reperfusion.   Our results show that the 
addition of 0.05µl and above of both isolated control and RIPC plasma exosomes 
confer cardio-protection against simulated our ischaemia reperfusion. (Table 15, Figure 
23)  
Table 15 - Table showing the results of survival analysis of invitro model of 
ischaemia reperfusion injury using rat cardiomyocytes. Results show % cell 
death in normoxia, untreated samples. Then with the addition at re-oxygenation 
of Insulin as a positive control and finally serial dilutes of control and RIPC 
plasma exosomes (5µl-0.0005µl, n=5). 
Treatment at Re-oxygenation (n=5) Average % Cell Death 
Normoxia 10.68 
Untreated 53.56 
Insulin 14.26 
5 µl exosomes 
Control 17.37 
RIPC 17.45 
0.5 µl exosomes 
Control 24.14 
RIPC 19.40 
0.05 µl exosomes 
Control 31.28 
RIPC 28.23 
0.005 µl exosomes 
Control 57.33 
RIPC 40.58 
0.0005 µl exosomes 
Control 71.35 
RIPC 64.78 
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Figure 24 Graph showing the results of survival analysis of invitro model of 
ischaemia reperfusion injury using rat cardiomyocytes. Results 
show % cell death in normoxia, untreated samples. Then with the 
addition at re-oxygenation of Insulin as a positive control and 
finally serial dilutes of control and RIPC plasma exosomes (5µl-
0.0005µl, n=5). 
 
Discussion 
Our results demonstrate that plasma exosomes are cardio-protective against IR injury 
irrespective if they are control or RIPC plasma exosomes. The protection conferred by 
plasma exosomes are comparable to Insulin, a known cardio-protective agent, used 
here as our positive control. These results suggest that plasma exosomes in general 
are cardio-protective and may not have a mechanistic role in the cardio-protection 
conferred through RIPC.  There is some divergence in the degree of cardio-protection 
with the addition of 0.005µl of control and RIPC plasma exosomes. At this 
concentration RIPC exosomes still provide some degree of cardio-protection yet the 
control plasma exosomes do not. This however may simply be due to the lower 
concentration of exosomes in the control sample.  We know from our previous 
experiment that RIPC exosome samples have a higher concentration of exosomes. 
Conversely this could also provide a tentative mechanism linking the cardio-protection 
conferred through RIPC with plasma exosomes. Does the effect of increased plasma 
levels of exosomes seen after RIPC help with cardio-protection, rather than a plasma 
exosome with a differing content?  
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CHAPTER 
 
Discussion 
Exosomes are increasingly thought to play a novel role in intracellular communication. 
The primary aim of this thesis was to begin to explore the potential role for plasma 
exosomes in the mechanism of RIPC. Could plasma exosomes provide a mechanistic 
explanation for why the brief and intermittent ischaemia of a distant organ confers 
cardio-protection against IR injury?   
To explore this it was imperative to first establish protocol for isolating human plasma 
exosomes. At the time of embarking on this project exosomal research had largely 
been carried out using exosomes isolated from the supernatants of cultured cells. The 
optimal method of plasma exosome isolation, purification and characterization was 
subject to continuing investigation and is not straightforward for a number of reasons. 
Firstly, human plasma is complex containing erythrocytes, platelets, lymphocytes and 
monocytes etc. as well as being exposed to endothelial and other cell types, thus the 
source of exosomes in plasma still has a degree of uncertainty. The vast majority of 
exosomes in human plasma are thought to arise from platelets and erythrocytes. The 
most commonly used technique for exosome isolation is a process of serial differential 
centrifugation and ultracentrifugation 244. This process relies on the physical properties 
of exosomes in terms of their size and sedimentation coefficient. Some protocols 
include a step in which exosomes are separated on a density gradient according to 
their buoyancy, although this adds a further degree of complexity and potential 
variability to the protocol. It is thought that ultracentrifugation can cause plasma 
exosomes to aggregate together as a consequence of their protein and lipid rich 
coating. This tendency for aggregation can significantly reduce the yield from isolation 
through ultracentrifugation, and can potentially cause co-precipitation of non-exosomal 
proteins that are trapped in the aggregates. Recognizing this challenge it was only in 
6 
100 
late 2013 that Witwer and colleagues published their paper attempting to standardize 
sample collection, isolation and analysis in extracellular vesicle research252. 
The volume of human blood available of exosome isolation was also a limiting practical 
factor. In fact at the beginning of this project, the one paper that had described isolation 
of plasma exosomes from human blood, had isolated plasma exosomes from a 
significantly larger volume (400-600 ml) of blood than was available to our group 
(72ml). The limitation was largely due to the ethical constraints of obtaining much 
larger blood volumes from human participants as well as the practical challenge of 
persuading participants in providing such. Additionally, the Eppendorf centrifuge 
system that was available for use in our laboratory would only allow centrifugation of 
60ml of plasma at a time to produce platelet free plasma and there was a similar 
limitation in volume with the ultracentrifuge. Isolating exosomes from a greater quantity 
in blood would therefore involve further centrifugation steps, 60ml of plasma at a time, 
necessitating storage of plasma in ice till it could be then also centrifuged. Our concern 
with this process was that this waiting time would potentially cause the platelet 
component of the plasma that is a rich source of exosomes to release exosomes and 
contaminate the sample. Nonetheless, for research in this field to remain viable within 
the scientific community, protocols must be devised to allow the isolation and 
purification of plasma exosomes from a small sample of plasma. 
After multiple iterations of our isolation protocol of differential centrifugation and 
ultracentrifugation we were able to establish a protocol for isolation of plasma 
exosomes from human blood. The isolation of exosomes was confirmed through the 
presence of cup shaped vesicles by electron microscopy, of the expected size range 
(50-100nm diameter). Though spherical in solution, the cup shape is thought to be due 
to the vesicles collapsing during the drying procedure for electron microscopy.  
Our next challenge was to produce exosome samples that we felt were pure enough to 
take forward for further experiments. We embarked on this through an experiment of 
isolating human plasma exosomes and putting them through a range of one to five 
serial ultracentrifugation washing steps. Albumin is the most abundant protein in 
plasma. We therefore used albumin as a surrogate marker for impurity and each 
sample of human plasma exosome was analyzed through western blotting. We were 
able to demonstrate that 3 ultracentrifuge-washing steps provided the best balance of 
purity versus exosome quantity. Although exosomes were undoubtedly more pure after 
4 ultracentrifuge steps, the yield was unacceptably low, and would make subsequent 
analysis impossible. We acknowledge that this method is certainly not perfect, and that 
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there will still be significant contaminating protein, however there remains no perfect 
procedure to isolate pure exosomes, nor consensus on what is the optimal 
procedure252. Subsequent groups have used alternative methods to achieve greater 
purity. These methods have involved affinity purification using exosome membrane 
antigens or sucrose density gradients separating vesicles based on their buoyant 
densities. Kalra and colleagues attempted to evaluate these strategies of exosome 
isolation and concluded that the density gradient method of exosome isolation yielded 
the more pure samples from human plasma. However they also acknowledge that the 
density gradient method was laborious and cannot be effectively used yet in the clinical 
setting for biomarker analysis253. Affinity purification typically results in relatively high 
purity of exosomes, at the expense of yield. Furthermore, the method requires the use 
of one or more antibodies against specific marker proteins, and therefore the analysis 
is restricted to those exosomes that express the marker proteins. A number of easy-to-
use and inexpensive commercial kits are also available for exosome isolation such as 
ExoQuickTM (System Biosystems) and Total Exosome Isolation (Life Technologies). 
The exact methods by which these kits isolate exosomes are not disclosed by their 
respective companies, but involve selective precipitation by a proprietary polymer. 
Though used by various groups and indeed these products do successfully isolate 
exosomes, the purity of the sample being produced is increasingly being questioned246 
. Pilot studies in our laboratory indicated that while yields of “exosomes” were high, the 
purity was low, as assessed by the appearance of bands by Western Blotting. As yet 
there is still no consensus amongst the scientific community how to best overcome the 
challenge of isolating exosomes human plasma in sufficient quantity and purity252. 
Having established a protocol for human plasma exosome isolation that satisfied our 
requirements for purity and yield, we then went on to probe the samples for known 
protein markers of exosomes: HSP70, CD63, CD9 and CD81. HSP70 and CD63 were 
consistently found in exosomes from the plasma from all participants. Interestingly, 
though classically in literature the molecular weight of CD63 in exosomes is described 
as 53 kDa. We consistently detected a signal at 26 kDa both in human plasma 
exosomes but also in concurrent work carried out on rat plasma exosomes. On further 
review, we ascertained that the molecular weight of CD63 protein itself is 26 KDa, but 
that glycosylation typically alters its size appearance by Western Blotting. It is not clear 
why CD63 ran at its native size in our experiments. The other typical tetraspanins 
tested, CD9 and CD81 were consistently undetectable in our samples. This again was 
consistent with the findings of other experiments within our group working on rat 
plasma exosomes. Upon further review difficulties with western blotting with exosomes 
are not uncommon and more so with plasma. Primarily difficulties arise due to the low 
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yield of protein and insensitivity of the primary antibodies with variability of success 
between differing companies producing the primary antibody. Alternatively, the exact 
complement of tetraspanin molecules may vary between exosomes of different 
sources, and CD9 and CD81 may not be present at high concentration in plasma 
exosomes. As this experiment was primarily designed to validate that we had 
successfully isolated plasma exosomes, the successful identification of HSP70 and 
CD63, in combination with other data (nanoparticle tracking analysis and EM – see 
below), was taken to be sufficient. We did not feel it necessary to further investigate 
using different primary antibodies of CD9 and CD81 from other companies.  
The ability to quantify exosome concentrations was critical in order to test our 
hypothesis that human plasma exosomes had a mechanistic role in the cardio-
protection conferred through RIPC. As discussed previously, for many years a reliable 
methodology of exosome quantification had not been developed and accepted. At the 
start of this project a new apparatus manufactured by Nanosight which was able to 
perform nanoparticle tracking analysis (NTA), had entered the market. Its 
manufacturers claimed the ability to accurately visualize and quantify particles in liquids 
from 10-2000nm in diameter. Based on the principle that the rate of Brownian 
movement of nanoparticles in a solution is related to their size and using the Stokes-
Einstein equation and that the rate of particle movement is related to a size/sphere 
diameter of the particle, the NTA machine and its computer software provided allows 
for the calculation of number of particles in a given solution and the distribution of 
particles in relation to size of particles. Movement is also dependent on temperature, 
so temperature is maintained at 37°C, and is monitored and corrected for. 
Using the NTA machine equipment we were able to re-affirm the successful isolation 
human plasma exosomes through visually demonstrating particles consistent within the 
exosomal range (50-100nm). Our isolation technique produced exosome 
concentrations consistently to the magnitude of 1x1011 particles per ml plasma. Of 
interest, our NTA analysis results showed the presence of some larger particles in our 
sample (100-300nm), though in much smaller numbers. These larger particles may be 
microvesicles, plasma proteins, or potentially other subcellular organelles. A potential 
limitation of NTA is that it is unable to distinguish vesicles from other similarly sized 
particles, but when our NTA data is taken in combination with EM and western blotting 
results, it strongly indicates the presence of high quantities of exosomes. To provide 
further confidence in the use of the NTA machine as a quantification tool we tested the 
variability of the NTA analysis machine on our samples. Inter-sample variation on 
taking dilutions for nanosight analysis was well within acceptable limits with a variability 
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coefficient of 2.4%. Having gained confidence in the NTA as a quantification tool for 
our human plasma exosomes we were able to demonstrate that our isolation technique 
for human plasma exosomes was also consistent and the variability (variability 
coefficient 8.6%) in exosome numbers produced from our isolation technique was 
within acceptable limits. This provides confidence that we had established a reliable 
and reproducible method of exosome isolation from human plasma. Lastly while 
working with limited resources of human samples as well as the time consuming 
protocol for isolation, it was important to establish the optimal storage conditions for 
exosomes that would allow for future experiments. Using the NTA machine we were 
able to show that the optimal storage conditions for exosome samples were at -80°C, 
which was consistent with other literature findings 252,253.  
As further evidence to demonstrate the presence of exosomal markers on the surface 
of isolated exosomes we utilized flow cytometric analysis. As evident from our western 
blotting experiments, protein and biomarker detection in exosomes themselves can be 
problematic due to the low protein yield and the probable lack of sensitivity of primary 
antibodies. Although flow cytometry is incapable of directly detecting particles of less 
than ~300 um including exosomes, we were able to make use of an alternative 
approach by adsorbing exosomes onto small, latex, microsphere beads244. In principle 
this technique should only detect proteins that lie on the surface of exosomes, so can 
also provide information as to the location of proteins, however we hoped that this 
technique would allow for easier biomarker detection and therefore provide semi-
quantitative tool in exosomal analysis. We successfully demonstrated by flow 
cytometric analysis the detection of classical exosomal proteins CD63, CD9, HSP70 
and CD81. Even the tetraspanin proteins, CD9 and CD81 that were not detectable via 
western blotting, using the same antibodies, were detected by our flow cytometry 
analysis. These results therefore support our hypothesis that flow cytometric analysis 
may be a more sensitive method for biomarker analysis of human plasma exosomes - 
certainly for those biomarkers or proteins that reside on the surface of the exosome.  
Lastly we aimed to establish an isolation method to detect miRNA from our human 
plasma exosomes. The extent to which plasma miRNA is contained within exosomes is 
still controversial. Some studies suggest that exosomes contain the majority of plasma 
miRNA197, while others find plasma miRNAs are mainly in argonaute complexes198. 
However, numerous studies have demonstrated the ability of exosomes to transfer 
miRNA to other cells 195,199 and miRNA have been implicated in both ischaemia 
reperfusion injury and heart failure234. The ability to regulate specific miRNA and their 
function could present a novel cardio-protective strategy. A reliable isolation protocol 
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for miRNA from human plasma exosomes would be required for future exploration of 
their potential role in cardio-protection in RIPC. Though in small quantities we were 
able to successfully isolate miRNA from our human plasma exosome samples. We 
observed signals from human plasma exosome samples for miR-16, snoU6 and 
GAPDH. UBC was expressed at close enough levels to be used as normalization 
control for GAPDH. SnoU6 is a better normalization control for our human exosome 
samples while RNU6B was not expressed at all in our samples. These results provide 
a protocol for further miRNA experiments on human plasma exosomes. Experiments 
comparing the miRNA content of RIPC and control exosomes can now be carried out. 
However we must exercise some caution. Extracting miRNA from exosomes relies 
critically on ensuring as pure a sample of exosomes as possible. From our previous 
western blot and nanosight experiments we are aware that there are still some serum 
contaminants in our sample. We have to be sure that miRNA observed in any further 
array testing is indeed coming from our exosomes and not contaminant protein. It is 
likely that improved isolation protocols will be identified in future, which may be a more 
appropriate exosome isolation protocol to then try and isolate microRNA from252,253. 
The mechanism of cardio-protection conferred through remote ischaemic 
preconditioning is not fully understood. Humoral factors are proposed to play a key 
role, yet the identification of the precise humoral factors have been challenging. Indeed 
it may be several humoral factors working in conjunction that lead to the cardio-
protection seen through RIPC. Exosomes have the potential to ferry proteins or groups 
of protein to a target organ or cell and thus confer cardio-protection. With an isolation 
protocol established we aimed to explore further the relationship between RIPC and 
circulating plasma exosomes in humans. In the following experiments we examined the 
effect the remote ischaemic preconditioning had on human plasma exosomes, both in 
terms of their quantity as well as content. Our first set of experiments looked at the 
effect of RIPC on the concentration of human plasma exosomes using NTA analysis. 
Our results show interestingly that remote ischaemic preconditioning consisting of 
three cycles of forearm cuff inflation and deflation consistently lead to a rise in plasma 
exosome concentration in all participants. This trend was also seen in the parallel rat 
exosome experiments carried out within our research group. RIPC human plasma 
exosomes were also shown to contain greater concentrations of exosomal proteins 
HSP70 and CD63. This compliments our nanosight data and supports the conclusion 
that RIPC indeed leads to a rise in human plasma concentrations. Aware that platelet 
activation can also stimulate the release of exosomes as well as microvesicles, the 
exosome isolation method was developed to minimize platelet activation as much as 
possible. Additionally preconditioning has been shown to decrease platelet activation, 
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in particular limb RIPC has been shown to prevent systemic platelet activation in 
humans164,254,255. This gives us confidence that the rise in plasma exosomes post RIPC 
is unlikely to be attributed to platelet activation. The rise in exosome concentration post 
RIPC stimulus may indicate a role for exosomes in the cardio protection that is 
conferred through RIPC. If human plasma exosomes are indeed cardio-protective, 
does RIPC confer its cardio-protection through increasing circulating plasma exosome 
concentrations, which then exert their influence on the myocardium? Further work is 
needed to determine whether the increase in exosome concentration is causal in the 
induction of RIPC, or whether it is an unrelated phenomenon. Answering this question 
at present is challenging. An interesting experiment could involve an in-vivo rat model 
of RIPC where one administers a drug or compound that blocks exosome release just 
prior to the RIPC protocol. Loss of cardio-protection that one normally associates with 
RIPC would suggest indeed the rise in exosome concentration post RIPC is integral in 
the mechanism behind RIPC cardio-protection. Unfortunately at present no such 
compound exists that selectively blocks exosome release, though there is some 
interesting progress within this area with Rab proteins being implicated in exosome 
release185. Further experiments revealed that peak rise in exosome concentrations did 
not occur immediately after the last cuff deflation (reperfusion) in the 3 cycles of RIPC 
protocol, but after a further 5 min of reperfusion. This suggests that the exosomes are 
not simply washed out of the limb post-ischaemia, but are released during the 
reperfusion period. The convention of using 3 cycles of 5 minutes of cuff inflation and 
deflation in clinical and laboratory studies of RIPC both is not particularly based on 
scientific evidence, but was chosen for historical reasons based on parallels with direct 
ischaemic preconditioning. There have not been any studies that have looked in detail 
whether fewer cycles confer a similar protection.  Assuming exosomes are causal in 
RIPC, our results may anecdotally suggest that 3 cycles of 5 min f cuff inflation and 
deflation are sufficient for induction of RIPC. However, no comparison was made with 
higher numbers of cycles of RIPC. Though beyond the scope of this project further 
experiments could be conducted to ascertain the precise point of rise in exosome 
concentration following RIPC. Could indeed one cycle 5 minutes of cuff inflation and 
deflation be enough to produce a similar response? It would also be interesting to 
determine the response in human plasma exosome concentration to further cycles of 
RIPC.  
An alternative hypothesis for the role of plasma exosomes in the cardio-protective 
mechanism of RIPC involves the release of human plasma exosomes post RIPC 
stimulus with specific cardio-protective cargo. RIPC has also been shown to protect via 
the pro-survival protein kinases of the RISK pathway. Traditionally these pro-survival 
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kinases are activated through G protein coupled receptors (GPCR). We looked to 
investigate whether particularly RIPC plasma exosomes these active pro-survival 
protein kinases of the RISK pathway and therefore confer cardio protection directly 
when released in to the cell. Through western blotting and FACS analysis we probed 
both RIPC and control human plasma exosomes for PI3-Kinase, AKT, MEK1/2, and 
ERK1/2. Despite multiple attempts, we could not demonstrate the presence of pro-
survival kinases directly in human plasma control or RIPC exosomes. This may simply 
be a limitation of working with samples that contain such a small amount of protein. 
However if the result is true, and indeed pro-survival kinases are not directly located in 
human plasma exosomes (especially RIPC exosomes), there may be other signalling 
proteins or growth factors within human plasma exosomes that may work at a higher 
level in the RISK pathway, and directly on the GPCR. Indeed HSP70 itself has been 
shown to have cardio-protective properties249–251, however this protein is seen in both 
RIPC and control exosomes. This could possibly explain a mechanism for cardio-
protection through plasma exosomes in general, however would not explain an 
exosomal mechanism for the cardio-protection conferred through RIPC as HSP70 is 
seen in both RIPC and control exosomes. Therefore one may conclude that RIPC may 
not produce human plasma exosomes with specific cardio-protective cargo but simply 
increase the concentration of human plasma exosomes and with this increase in 
concentration results in cardio-protection.  
Our primary aim for this project centred on the hypothesis that human plasma 
exosomes play a mechanistic role in the cardio-protection conferred through RIPC. In 
particular we hypothesised that RIPC involves the release of human plasma exosomes 
with specific cardio-protective cargo. To test this hypothesis both RIPC and control 
exosomes were added to an in-vitro model of IR injury using rat cardio-myocytes. If our 
hypothesis were true one would expect RIPC plasma exosomes to confer cardio-
protection while control plasma exosomes will not. The results of our experiments show 
that both the addition of 5µl of RIPC exosomes or control exosomes at reperfusion 
conferred significant cardio-protection and reduced cardiomyocyte cell death to 17 ± 
3% and 17 ± 4% respectively. A dose response experiment with the addition of serial 
dilutions of RIPC and control exosomes at reperfusion demonstrated that the addition 
of 0.05µl and above of both isolated control and RIPC plasma exosomes confer cardio-
protection against simulated our ischaemia reperfusion. Our results therefore 
demonstrate that plasma exosomes are cardio-protective against IR injury irrespective 
if they are control or RIPC plasma exosomes. The protection conferred by plasma 
exosomes are comparable to Insulin, a known cardio-protective agent, used here as 
our positive control. These results suggest that plasma exosomes in general are 
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cardio-protective and may not have a mechanistic role in the cardio-protection 
conferred through RIPC.  There is some divergence in the degree of cardio-protection 
with the addition of 0.005µl of control and RIPC plasma exosomes. At this 
concentration RIPC exosomes still provide some degree of cardio-protection yet the 
control plasma exosomes do not. This however may simply be due to the lower 
concentration of exosomes in the control sample.  We know from our previous 
experiment that RIPC exosome samples have a higher concentration of exosomes. 
Tentatively this may support our previous hypothesis that RIPC may lead to a rise in 
serum plasma exosome concentrations above and beyond a threshold that results in 
cardio-protection. Although not quite proving our initial hypothesis we have been able 
to show that human circulating plasma exosomes are cardio-protective. Its role in RIPC 
is yet to be established. A potential further experiment to add weight to our discovery 
would be to additionally add the exosome free plasma supernatant in to our in-vitro 
model of ischaemia reperfusion injury. If plasma deplete of exosomes failed to cardio-
protect this would provide further strong evidence for their role in cardio-protection. 
One could confirm an exosome free supernatant through nanosight appearance as well 
as the lack of a positive signal of CD63 on a western blot. Adding human plasma to rat 
cardiomyocytes has obvious limitations. A further interesting experiment would also be 
to add human plasma exosomes in to a human atrial trabeculae model of ischaemia 
reperfusion and testing if similar cardio-protection is seen. 
Recently Ferdinandy and colleagues published a paper exploring a similar hypothesis 
to this project. Using the effluent model of RIPC, perfusate from rats undergoing 3	 ×	 
5-5 	 min global ischemia and reperfusion (IPC) were depleted of exosomes by 
differential ultracentrifugation and was then given to another set of recipient isolated 
hearts. Interestingly there results also describe a marked increase in exosome release 
following an IPC stimulus. Additionally they showed that exosome deplete perfusate 
failed to exert cardio-protection in recipient hearts when compared to normal IPC 
perfusate. The group concludes exosomes released from the heart after IPC are 
necessary for cardio-protection by RIPC suggesting cardio-specific cargo in 
exosomes256226. This is in contrast to our results where RIPC exosomes exert similar 
cardio-protection to control exosomes. On further reflection an explanation for this 
disparity may be that RIPC is a complex cascade of interactions between blood cells 
and neuronal signals that the effluent model of RIPC does not truly capture. 
Additionally the effluent model perfusate will also be considerably more dilute than 
blood thus the concentration of exosomes would likely be much less. It may be that 
IPC increases the concentration of exosomes in the perfusate above a threshold 
needed to provide cardio-protection. Interestingly taken together our findings as well as 
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Ferdinandy and colleagues, the cardio-protective properties of plasma exosomes are in 
contrast to those of microvesicles that appear to have detrimental effects in RIPC257.   
The mechanism by which circulating plasma exosomes exert cardio-protection is yet to 
be identified and therefore must be the focus of future work within our group. Cardio-
protection is seen rapidly after exosome perfusion suggesting an immediate 
mechanism. Upon analysis of both control and RIPC exosomes we could not 
demonstrate the presence of pro-survival kinases directly in human plasma control or 
RIPC exosomes. There may be other signalling proteins or growth factors within or on 
the surface of human plasma exosomes that interact directly with the plasma 
membrane and GPCR in the myocardium which then in turn activate further 
downstream traditional cardio-protective signalling pathways such as the RISK 
pathway described previously. There is already an established relationship between 
the RISK pathway and exosomes. Mesenchymal stem cell (MSC) exosomes have 
been shown to confer their cardio-protection via the RISK pathway. MSC exosomes 
have been shown increase ATP levels, decrease oxidative stress and activate 
PI3K/Akt pathway258. Additionally cisplatin-induced oxidative stress kidney injury was 
attenuated by exosomes from human umbilical cord mesenchymal stem cells 
protecting via ERK1/2256. A simple experiment to ascertain if the RISK pathway is 
involved in the mechanism of protection from plasma exosomes would be to western 
blot the cardiomyocytes, both with and without the addition of exosomes, for AKT and 
ERK. Increased signals of either would suggest that cardio-protection from exosomes 
follows traditional pro-survival pathways. 
Identifying the potential signalling protein or growth factor that confers cardio-protection 
in plasma exosomes is the next challenge. HSP70 is a potential candidate. HSP70 is 
found in all prokaryotes and eukaryotes. Initially thought to be chaperone proteins, 
which facilitate the folding naïve, and refolding of denatured proteins aiding protein 
trafficking. Previously thought to largely intracellular, HSP70 is secreted and released 
outside cells by exosomes after stressful stimuli and the cardio-protective properties of 
HSP70 are also well established249–251. Could the release of HSP70 from exosomes 
lead to the cardio-protection seen in our invitro survival experiments? To test this 
hypothesis one could add a HSP70 inhibitor in to the invitro survival experiments along 
with the circulating plasma exosomes. If cardio-protection were lost this would suggest 
a role for HSP70. Other possibilities include proteins such as Il-10, CGRP and Stromal 
Derived Factor-1α (SDF-1α). Work from within our group has recently shown that RIPC 
results in an increase in circulating levels of SDF-1α. Additionally the blocking of SDF-
1α using CXCR4 results in the attenuation of cardio-protection conferred by RIPC86. 
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Could plasma exosomes contain SDF-1α? Exosomes may indeed ferry a number of 
pro-survival proteins and growth factors and protect via multiple mechanisms. 
MicroRNA are another potential cardio-protective candidate located within plasma 
exosomes. Though unlikely to be involved in immediate setting of ischaemia 
preconditioning, there maybe a role in the mechanism behind delayed or “second –
window” of preconditioning.  
Conclusion 
In conclusion we have developed a viable and reproducible protocol for the isolation 
and analysis of human plasma exosomes. We have also shown that RIPC leads to a 
rise in circulating plasma exosomes and importantly plasma exosomes appear to be 
cardio-protective against ischaemia reperfusion injury. Exosomes therefore represent a 
new frontier in cardio-protection and further investigations are needed.  
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